initi coverag medic suppli
think med-tech continu pleas growth extend roar
initi coverag medic suppli devic med-tech sector posit view
med-tech consist top perform within healthcar group last year driven
strengthen fundament innov trend multipl expand think outlook
remain strong expect revenu sector sustain growth mid- upper-singl digit rang
translat double-digit earn growth
initi coverag follow stock
expect technolog differenti cost effect discuss continu intens real
innov devic strategi drive valu addit expect busi model
evolv devic compani diversifi revenu stream segment healthcar includ
servic drug/devic combin therapi med-tech compani increasingli focus offer
product procedur solut election-year rhetor unavoid med-tech offer
safe profil defens growth characterist
given outlook expect med-tech multipl support current level said think
signific multipl expans current level unlik key driver stock perform
therefor think investor remain select share high-qual compani
continu deliv strong fundament perform well stock lag group
acceler growth next two year view initi coverag stock
initi coverag medic suppli devic
think med-tech continu pleas growth extend roar
page
tabl content
initi coverag medic suppli devic
thought sector
perform overview
spine spinal cord stimul
deep dive spine market background page
initi coverag select compani spine
spinal cord stimul
deep dive cardiac monitor market background page
initi coverag select compani cardiac monitor
deep dive spinal cord stimul page
diversifi
initi coverag select compani diversifi
spine spinal cord stimul
page
initi coverag medic suppli
devic sector
page
initi coverag compani med-tech space
factset strh estim price close
page
bear casebas casebul casebuymedtron biomet hold medic inc class technolog buybiotelemetri buyaxon modul technolog perform market cap larg capmid capsmal captarget scenariosimpli return base case pt healthcar
initi coverag compani med-tech space
turnaround stori inflect point ahead zimmer biomet
high-growth high controversi name chang standard care irhythm axon
under-cov underappreci
pure-play real solut unmet need axon irhythm
pioneer robot space enabl minim invas surgeri globu
extens clinic data irhythm
offer full bag product time hospit consolid vendor
page
thought sector
year last decad healthcar outperform broader market
page
thought sector
consensu outlook still call high growth healthcar
consensu estim call revenu acceler sector revenu acceler impli healthcar space
expect one top growth sector year
bottom-lin street assum overal earn per share growth acceler healthcar
page
thought sector
acceler top-lin growth us medic devic
consensu estim compani includ medic devic measur ishar medic devic etf call top-lin
acceler
bottom-lin consensu estim impli continu double-digit earn growth next two year follow particularli strong
page
medic healthcar immunolog growthep growth healthcar
thought sector
medic devic driver out-performance
healthcar return lag broader overal market
howev medic outperform
healthcar slightli weaker year histor year perform driven larg growth medic devic stock
genom immunolog healthcar
measur ishar medic devic etf
page
thought sector
med-tech perform pull back modestli second half
 perform tale two halv excit outperform start year follow lacklust perform
first half year group well-ahead healthcar second half medic devic
under-perform healthcar view interest shift toward idiosyncrat invest biotechnolog
categori within healthcar lower valuat profil
genom immunolog healthcar
genom immunolog healthcar
measur ishar medic devic etf
page
thought sector
med-tech consist top perform within healthcar group last year
think med-tech uniqu sens offer defens invest opportun pair auspici top- bottom-lin growth
 medic outperform overal healthcar market past year deliv particular strength recent
year prior perform best within healthcar sector
measur ishar medic devic etf
measur ishar biotechnolog etf
page
devic devic immunolog healthcar devic devic provid provid healthcar healthcar healthcar provid devic provid devic provid healthcar devic provid provid devic healthcar provid immunolog healthcar provid healthcar healthcar healthcar healthcar devic provid devic healthcar healthcar healthcar healthcar provid healthcar healthcar devic healthcar healthcar immunolog healthcar healthcar healthcar immunolog healthcar healthcar immunolog healthcar nagenom immunolog healthcar nagenom immunolog healthcar nagenom immunolog healthcar nagenom immunolog healthcar healthcar immunolog healthcar healthcar immunolog healthcar healthcar
thought sector
perform driven valuat histor level
averag ev/sal multipl medic devic compani expand almost last year
end multipl expand
price-to-earnings multipl ntm earn end price-to-earnings multipl
expand
includ compani ishar medic devic etf
page
thought sector
sever theme
technolog differenti cost effect discuss continu intensifi real innov
continu drive valu
busi model evolv continu evolv device/servic drug/devic
combin surfac think medic technolog valuat sustain level think
diversif revenu stream segment healthcar may act hedg see undu
pressur devic
election-year rhetor unavoid medic technolog gener fare well elect
year med-tech offer defens growth qualiti compani establish revenu stream offer
price transpar attract margin profil play market fairli well-defin product approv
reimburs pathway
believ signific multipl expans unlik driver stock price beyond underli
growth investor strategi may lean toward valu play growth reason price least
earli part year
expect steadi continu tuck-in activ larger transform deal healthcar
simpli proven challeng integr
page
initi coverag compani med-tech space
favorit theme mind
larg cap favorit idea zimmer
biomet buy think stock still
signific room run current level
stock trade discount group
yet growth improv
top- bottom-lin
mid-cap favorit idea
buy research suggest sale forc
headcount stabl think current
valuat reflect inflect point
ahead well potenti behind new
product develop
believ buy also
steadi outperform next month
addit like globu medic buy
offer remark
consist perform last five
year certainli may continu deliv
think may noisi year
concern around pend wright medic
deal new competit larg joint
robot market initi hold
think compani surpris
impress investor new innov either
expect launch next
month believ develop
base review compani patent
portfolio buy well
quintessenti turnaround stori
think play next month
given deep dive research market
small cap favorit idea irhythm
buy buy irhythm
analysi sever reimburs scenario
suggest concern overdon current
valuat simpli doesnt reflect compani
growth profil potenti si-bon
view perfect exampl compani list
potenti growth driver
expect lead acceler growth
profil fulli reflect stock price
addit think investor
axon buy given assess
compani social media announc
think suggest earli success commerci
launch unit state proprietari
work buy analyz compani
vilex deal suggest concentr user base
therefor abil extend new market
fairli easili halo effect
broader busi support potenti
acceler revenu come year
buy name get
enough attent investor think
room run valuat clearli
doesnt reflect compani earn potenti
view
page
deep dive spine market background
page
deep dive spine
view sever defin characterist success compani spine market includ
pure-play spine player differenti either truli uniqu product focus sale team uniqu commerci approach
med-tech compani thing hospit sell full portfolio spinal solut
compani keen latest trend grow organ inorgan invest opportun innov
implant new titanium porou technolog mpd innov around procedur enabl technolog
robot
exposur higher-growth segment within spine implant market includ limit minim invas surgeri
deform motion preserv
compani data drive reimburs decis influenc societi guidelin impact valu access committe decis
partner lead surgeon develop new product hospit provid offer cost-effect solut
get spine market excit market medic technolog high growth though think grow
come price pressur albeit stabl mani product fact commodit henc price pressur
howev larg market annual revenu grow categori distinctli underappreci includ minim
invas surgeri robot importantli innov still reward spine
page
deep dive spine market background
given complex structur spine commonli suscept condit lead signific pain patient back pain second
common symptomat reason physician visit
appendix detail review spine anatomi relev procedur
number estim
spine surgeri per year
number adult
estim chronic
number adult
estim high-
pain day everi day past month
limit life/work activ day everi day past month
page
page
deep dive spine market background
 didnt spine market slow
began see deceler spine market growth rate report publicly-trad spine compani though singl explan
slow
remain debat unifi explan underli caus think combin effect follow
insur pushback high deduct plan two commonly-cit hypothes may impact market growth
mani compani surgeon contact indic increas preauthor denial spine case said mani
surgeon also suggest spine case ultim end approv though path payment bit convolut
histor
small privately-held compani take share data point publicly-trad compani seem suggest spine market
slow though mani small mid-siz privately-held spine compani continu grow captur market
share recent year compani exhibit nass realiz unlik one two small compani
would impact market growth collect believ could billion total annual revenu come smaller spine
compani therefor growth privat compani certainli impact overal market growth
biolog compani began invest porou technolog titanium print even porou peek implant one cite
benefit porou devic help facilit bone growth better fusion reason becom convers
amongst clinician whether reduc amount biolog use spinal procedur think unlik culprit
today surgeon speak still use biolog implant topic convers amongst surgeon commun
therefor least dynam monitor
spinal cord stimul spinal cord stimul market acceler debat around whether growth
come expens spinal implant procedur industri sourc private/publ compani surgeon sale repres mix
perspect topic though believ hypothesi unlik physician gener segment patient mechan
surgeon increasingli employ hospit anoth hypothesi surgeon increasingli employ hospit
like take paid vacat year surgeon take time away hospit number procedur perform
could lower
page
deep dive spine market background
 what go spine market late
market start stabil latter part market estim grew low-single-digit rang
consist histor growth rate howev sentiment still seem neg therefor stabl market growth good enough
base first nine month
year spine market stabl
think pretti clear base
result today spine market
continu challeng stryker
spine divis
flat quarter line
global spine market
make prognost
 market think
still flattish growth nuvas
spine busi continu see
market soft mid-single-digit
us spine
market continu stabl
intern estim
grew approxim
quarter compar
approxim flat growth
last month
weve seen overal
slowdown marketplac
due reimburs issu
believ
grow
continu encourag
growth rate
backdrop overal spine
market trend rel
flat remain stabl
page
deep dive spine market background
 what trendi
titanium porou implant
mani compani launch new porou devic made titanium recent year titanium use spine decad new
surgeon prefer shift back forth titanium polyetheretherketon peek surgeon prefer peek implant
recent year given materi radioluc therefor easili visibl x-ray imag howev newer titanium technolog increasingli
porou design allow better visibl x-ray imag improv boni ingrowth fusion rate reason expect
titanium porou implant continu grow come year
expand cage also new globu medic origin built brand around expand technolog though technolog seem
resurfac convers surgeon compani launch launch new product expand featur there
convers expand devic may help surgeon find better sagitt align spine may part support recent interest
technolog
histor robot spine perceiv bulki expens limit certain procedur percept chang weve
seen increas surgeon interest compani innov relat robot technolog enabl better surgeri current
three main player spinal robot market combin instal base rang unit though less spine surgeri
perform assist robot system accord
player
zimmer biomet acquir med-tech juli
sell robot today offer puls platform expect contribut
sell rosa spine system
compani expect first-in-man robot procedur end
acquir mazor origin partner mazor launch
mazor late compani instal base unit
work capabl integr system stealth navig spinal
globu launch excelsiu estim
instal base system recent
globu showcas new imag system expect launch late
page
compani like spine
page
initi buy pt
page
appli price-to-earnings multipl discount median med-tech larg cap peer group ep estim deriv
pt hold-rat share
deceler deterior spine end market growth includ signific chang reimburs and/or price headwind
becom materi wors
competit dynam materi chang larger diversifi player refocus spine market
product launch includ puls futur robot capabl gain traction market underwhelm vs expect
oper margin expans plan take longer expect materi
page
scenariobear casestrhbul ev/ebitda multipl contract revenu growth slow little/no contribut puls margin flat next yearsassum ev/ebitda multipl expand modestli revenu growth sustain modest contribut puls margin expans ev/ebitda multipl expans still trade discount ev/ebitda basi revenu growth modestli acceler ebitda margin expand ahead expectationsupsid vs current healthcar
incorpor grown fourth largest spine compani largest
pure-play market estim billion world-wide compani focus develop
minim invas surgic product procedur integr solut spine surgeri best-
recogn pioneer xlif extrem later interbodi fusion techniqu allow
surgeon access spine side bodi oppos front back
compani maximum access surgeri platform help enabl minimally-invas surgeri
includ later procedur platform includ proprietari software-driven nerv detect
avoid system intraop monitor iom servic support offer
clinic servic maxcess integr split-blad retractor system
addit offer extens offer special implant biolog spinal surgeri
includ fixat devic view full-servic provid environ hospit
consolid number vendor use compani commerci releas puls
system autom platform incorpor neuro-monitor surgic plan rod
bend navig long-term robot
compani bucket revenu three categori includ
 spinal hardwar revenu includ implant
fixat product use broad set spinal case
 surgic support revenu
intraop monitor iom servic dispos biolog
addit enabl technolog includ use spine surgeri
includ puerto rico revenu
page
compani file strh estim
stock watch think revenu earn growth acceler thesi hing compani
abil stabil strengthen top-lin growth profil time expect focu shift compani long-term earn potenti
believ underappreci believ revenu acceler driven improv core spine implant busi view
puls roll-out follow grow level focu robot becom increasingli tangibl second part
meaning catalyst busi addit stock januari low vs
time-frame share still trade in-lin septemb level discount peer valuat profil make share nuvas
particularli compel one rel valu stock high-multipl med-tech smid-cap world
point support thesi
think revenu growth better expect fourth-largest provid global spine market estim
billion recogn leader minim invas surgeri mi sub-seg market consist grow above-market
rate materi exposur intern also outpac domest spine market addit compani recent invest grow
sub-seg market histor under-penetrated includ complex deform analysi compani sale forc
linkedin show headcount stabl better enabl compani capit opportun reason given
potenti halo effect newly-launch puls think core spine revenu growth acceler next two year think
spine market rel stabl potenti show sign improv next sever year return predict growth low
singl digit howev thesi doesnt hing complet market rebound
puls interest increas focu robot shift sentiment believ begin discuss tangibl
metric puls pipelin opportun relat system think puls could add million revenu consensu model
alreadi begin includ puls though think potenti halo effect core spine busi well-appreci manag yet
frame anticip contribut post-launch expect provid conserv guidanc guard-rail earli
oper margin free cash flow gener best-in-class oper margin start recov estim
bp year-over-year see sever driver could push metric next five year compani invest
sever initi today includ launch develop puls though steadi improv next month give
investor confid compani long-rang margin goal potenti meaning free cash flow earn power
page
later compani alway later compani
approach
platform enabl
compani file present
first address
align
procedur
first offer
platform
page
matter stock item grow flat market
strh thought think grow mid- upper-singl digit
nuvas focus one attract segment spine implant market minim invas surgeri mi repres littl
global spine market expect could least time
 spine market whole grow rang lean toward low end rang recent year mi
segment grow expect continu grow above-market rate focus effort mi market
expect continu grow segment one mi area particularli strong later market estim
global estim still own later market today
addit revenu today come intern market also grow faster clip domest
page
matter stock item grow flat market
strh thought think grow mid- upper-singl digit
also remain under-penetrated sever fast-growth sub-seg market includ complex deform market
market share still singl digit rang last year compani made meaning invest area spine
compani recent launch expect launch steadi cadenc new product sever area remain under-index
market share segment
page
matter stock item grow flat market
strh thought think grow mid- upper-singl digit
next year expect grow spinal hardwar busi least today
segment least today
nuvas exposur later market million today estim later market grow rate overal mi
segment rang mid-point simpli hold market share later market estim later
exposur alon contribut million compani goal split intern
relat area potenti contribut increas market share complex today low doubl digit rang
think complex exposur could contribut million increment revenu note complex spine segment own
primarili johnson johnson togeth estim still market recent
acquisit complex spine leader expect could benefit near-term potenti integr disloc
consid compani intern goal note intern market grow high singl digit rang consist
histor growth rate compani simpli grow high end current run-rat well-below prior year expect
recov compani abl deliv million increment sale rel million target
certainli wont item contribut think size three item togeth help frame compani combin
increment revenu goal achiev
bottom line think manag long-term revenu goal
achiev comfort durabl revenu
growth compound-annual-growth-rate next year
despit turnov weve seen leadership level last
month analysi linkedin profil found sale
forc headcount remain fairli stabl recent quarter
page
last synth compani formerli ldr sale employeescompanygrowth healthcar
matter stock item puls actual matter
strh thought ye think new capabl shift sentiment
puls
puls launch juli design address exist shortfal robot spine case improv workflow
system includ neuro-monitor capabl surgic plan rod bend bendini radiat reduct lessray imag navig
function time also incorpor autom robot
expect compani discuss pipelin opportun relat puls cours
first launch
first launch
acquir
siemen
analyt
page
matter stock item puls actual matter
strh thought ye think new capabl shift sentiment
nuvas expect increment growth next
year surgic support busi includ devic
enabl technolog segment expect one key driver
enabl technolog busi nuvas puls
integr technolog platform model revenu contribut
though compani indic start contract
puls even collect sign purchas order system
wait beta phase complet deliv instal
system first quarter revenu contribut expect
sale could choppi normal first month
compani yet comment price believ
puls system could price bit exist robot system
estim price point lessray alon
per system expect puls price rate howev
nuvas focus core spine account estim
opportun could still meaning
addit note globu medic first launch
robot space compani sold system first
month sold system half cost
robot could repres approxim million increment
revenu first year post-launch
seem consensu alreadi includ million
contribut puls target repres
basi point growth next year therefor exclud contribut
puls street seem model deceler growth
think unlik given puls help support
uptak within core spine busi compani invest
heavili area under-penetrated today see item
what next
nuvas plan offer automation/robot capabl part
puls platform though yet submit approv fda
expect first human case like second half
launch target
beyond robot think real opportun captur data
analyt use puls technolog expect
increasingli valuabl come year insur
hospit seek reduc cost system
addit expect work surgeon develop
smart implant use puls time
bottom line expect low think puls current
form contribut least basi point growth
think robot offer real potenti catalyst
page
estim segment contribut nuvas healthcar
matter stock item margin stori
strh thought ye think opmargin achiev time
provid guidanc non-gaap oper margin
expect metric rang
expect deliv high end guidanc rang
would basi point margin expans
compani need show modest improv
fourth quarter reach goal consist deliv
sequenti increas metric last
year
addit expect oper margin could higher
exit current sell-sid estim beyond
though mid-term estim call
basi point expans basi point expans
total next two year
everi basi point oper margin upsid
model compani could deliv nickel upsid ep
target
key driver non-gaap oper margin
expans mid-teen today intern
scale manufactur effici asset effici recent
compani promot head manufactur new global
manufactur qualiti assur real estat
manag new leadership function align
compani goal continu gain oper effici
oper margin move higher tax rate
come time expect compani continu
grow invest sit revenu today
grow time price pressur like
remain headwind spine
oper margin
year
nuvas file strh estim
page
matter stock item margin stori
strh thought ye think opmargin achiev time
believ track deliv margin expans next year believ compani could
earn per share compar
compani state goal year call margin expans well-ahead peer group impli substanti earn power free
cash flow even low end forecast pair oper margin expans lower effect tax rate improv inventori
day hand asset effici compani impli free cash flow could million million
bottom line revenu recoveri first step near-term think compani depress margin profil start recov
real earn power year period
page
incom interest pre-tax tax after-tax dollar valu mm except per share itemssourc strh estimatesearn potenti rang oper margin outcom healthcar
select member execut leadership
prior mr
barri serv svp
presid surgic
innov largest
busi unit
annual revenu
role led
employe differ
member bod
novemb
manufactur site
prior combin
covidien
mr barri led
unit covidien
respons
develop global
lead us
year
commerci execut
leadership role
jan
dale wolf respons
suppli chain field
op real estat
facil busi
previous mr wolf
vice-president manufactur
led west
prior join nuvas
two decad gener
electr ge variou
mr link longest-
employe
team join
compani origin
sale
held sever role
time compani
corpor
evp us sale
respons
includ product
market logist
clinic research
prior time
posit depuy
orthoped depuy
evp cfo
mr harbaugh
newest addit
execut team bring
year
financ busi
strategi op management
join plc
held role
presid specialti
vice-president intern extern
prior current
posit ms hatcher
intern
commun
current role
respons nuva
relat intern
prior join ms
corpor
commun cubic
carefus sempra
prior current role
mr mcclintock serv
commerci
previous held
posit cfo
account treasuri
tax function well
procur facil
posit covidien
mr harbaugh overse
financi aspect
plan analysi tax
treasuri
year
sever sale
sale leadership
primarili focus
exclus
mr mcclintock
respons us
relat sale servic
strateg account
annual perform bonu determin
long-term incent award determin
current year non-gaap ep total target valu ttv
non-gaap optg margin expans year ttv
revenu growth year ttv
vice-president hires/departur captur linkedin last month
proxi perform goal lti
compani file linkedin
vice-president hr
departur titl ytd
departur titl last month
departur titl last month
offic left compani
presid global orthoped smith
sever public compani board
consult co-found ortho compani
evp peopl cultur
chief peopl offic dosist
vice-president advanc steril product
sever product divis vp depart januari
like strateg decis compani
hire went direct competitor
evp cervic biolog alphatec
vice-president research health informat
vice-president financ corpor control -alphatec
page
compani report strh estim
page
initi buy pt
page
appli multipl discount median mid cap med-tech peer group ebitda estim
deriv pt buy-rat share
deceler deterior spine end market growth includ signific chang reimburs and/or price
headwind becom materi wors
competit dynam materi chang larger diversifi player refocus spine market
product launch includ excelsiu solut emerg technolog gain traction market
new area musculoskelet space includ trauma hip knee take longer expect contribut
and/or prove challeng market grow share
page
scenariobear casestrhbul ev/ebitda multipl contract core revenu slow ebitda margin contract next two yearsassum ev/ebitda multipl maintain current level core revenu continu grow modest ebitda margin expansionassum ev/ebitda multipl expand core revenu grow quickli expect enabl technolog contribut revenu expect modest ebitda margin expansionupsid vs current healthcar
compani root spinal implant market globu origin pioneer expand devic
solut allow intraop custom patient anatomi year track record
rapid product develop commerci compani expand offer full suit
spinal implant product continu launch steadi spate new product year
engin expertis new product develop capabl globu expand offer
includ enabl technolog robot imag extens product offer area
musculoskelet market globu activ sell orthoped trauma market portfolio
fractur plate compress screw intramedullari nail extern fixat expect move
larg joint market come year acquisit skelkast august
enabl technolog busi globu includ imag navig robot inr assist
surgeri solut today compani sell excelsiu platform robot guidanc navig
system use minim invas open spine surgeri globu expect expand
enabl technolog product line includ larg joint robot capabl imag system
incorpor delawar
compani file strh estim
musculoskelet solut revenu
includ implant devic biolog
surgic instrument use spine orthoped
neurosurg procedur
enabl revenu
imag navig robot
approxim globuss revenu come
intern market though major sale today
come unit state
page
globu alway fit sweet spot spine market theyr compani larg enough view full provid spine product small
enough innov bring new product market quickli undoubtedli compani reinvigor brand recent year reinvent
best-in-class compani believ made right strateg decis controversi time becom leader spine
ultim leader musculoskelet categori excelsiusgp robot launch key compon stori recent year
think still room grow spine categori addit sens remain level skeptic compani abil
execut trauma larg joint opportun abl maintain industry-lead margin profil howev
compani demonstr abil balanc multipl initi maintain oper margin launch new market
stock isnt cheap in-lin late level lot happen sinc view augment valu
still lot runway excelsiusgp growth opportun core spine expect globu abl drive above-market
growth core spine busi driven continu steadi innov cadenc new product launch synergist opportun
excelsiusgp robot system think compani continu innov excelsiu system time expect integr
new imag platform also offer augment realiti capabl think core spine robot system alon could contribut million
revenu revenu imag platform augment realiti capabl uncontempl estim
expect trauma larg joint reason understand investor skeptic trauma still healthi level
skeptic relat launch larg joint though revenu expect busi segment fairli modest addit
applaud manag creativ diversif strategi musculoskelet market allow compani access much broader divers
opportun time
think skeptic around margin contract overdon expect globu maintain low- mid- adjust ebitda margin profil
next sever year model adjust ebitda make globuss profit profil one best
medic technolog concern whether compani abl sustain profit current level on-going
invest trauma larg joint orthoped enabl technolog segment believ compani maintain margin
rang margin profil translat strong free cash flow come year also expect globu use healthi cash posit
nearli million debt continu invest tuck-in technolog acquisit commerci scale bolster presenc new area though
compani gener price-sensit highli select busi develop process
page
start spine
technolog
launch
robot
system
found
focu spine
compani file transcript
trauma
acquir hip
page
globu medic matter stock item globu execut initi outsid spine
strh thought ye think trauma larg joint meaning contributor time
globu invest new product develop enter global trauma market compani began publicli discuss
initi area receiv first clearanc trauma may first case shortli thereaft
septemb compani press-releas launch march showcas product american
academi orthoped surgeon aao annual meet cover major orthoped trauma market time includ fractur
plate compress screw cannul screw intramedullari nail extern fixat product
compani continu round product portfolio trauma build
set hire new sale repres support broader launch
may globu also appoint daniel gregori vice-president sale
emerg orthoped trauma divis join depuy synth trauma
area vice presid sale dr gregori join globu
year sale sale manag experi orthoped
trauma second quarter scavilla evp chief commerci
offic took gener manag role trauma busi
summer compani experienc manufactur
suppli chain challeng led delay full commerci roll-out
issu mere inevit grow pain view linger
bit compani expand intern extern product
capac end first quarter larg resolv
think trauma busi contribut million full year
back-half weight globu disclos trauma contribut
immateri today estim million compani
indic trauma busi grew sequenti
found trauma hire linkedin includ
nearli hire commerci team alon
page
globu medic matter stock item globu execut initi outsid spine
strh thought ye think trauma larg joint meaning contributor time
globu develop robot solut total joint hip knee procedur last sever quarter expect launch
system late
second quarter globu announc acquisit stelkast manufactur total joint hip knee system long-
stand histori produc suppli product stelkast one origin supplier mako surgic first-mov larg joint
robot space acquir stelkast parent compani trigon hold disclos origin suppli agreement
mako surgic pre acquisit stelkast agreement date back
linkedin current employe stelkast
though two sale manag role work
compani find two distributor current sell
stelkast product well though commerci expect
globu need invest commerci infrastructur
support new market segment even limit
sale forc today estim stelkast gener
million annual revenu
assum skelkast implant revenu remain
essenti flat increment
revenu total joint robot system
bottom line think trauma larg joint
addit long-term growth profil
compani point consensu
isnt model signific contribut year
next larg joint particular essenti
page
strh estimatesestim segment revenu contribut medic million healthcar
globu medic matter stock item excelsiusgp still runway
strh thought think begin
excelsiu
globu medic acquir robotics-develop excelsiu origin excelsiu technolog co-found dr nichola theodor
chief spine section barrow neurolog institut director john hopkin neurosurg spine center dr neil crawford
overlap dr theodor time barrow neurolog institut join globu director robot technolog
acquir technolog
current featur excelsiu system includ eas use fact portabl surgeon wheel system one oper
room next highli accur guidanc capabl today system use conjunct imag platform
navig compon system allow visual represent implant instrument within bodi
excelsiusgp clear august subsequ launch globu unit state first quarter post-launch estim
compani place system end estim compani instal base robot system model
addit system placement
what market
today excelsiusgp spine robot system sell million think next gener capabl even complet next-gener
system help support mitig futur price pressur approxim spine center unit state though high volum
center could potenti purchas one system
next year compani expect launch new imag system combin intraop imag system compani complet
solut sell premium refer o-arm price around market essenti own
c-arm price think given weve seen globuss new imag system incorpor fluoroscopi high-
definit x-ray capabl system smaller imag platform potenti provid better imag qualiti sell least
in-lin o-arm therefor combin excelsiusgp robot imag system could sell nearli million addit believ
compani could potenti charg premium augment realiti capabl yet discuss think like develop
impact core spine growth
difficult quantifi impact core spine growth benefit use globu implant excelsiu imag guidanc capabl
use compani implant combin technolog elimin need use k-wire procedur therefor reduc time
case avoid potenti complic addit globu implant preload compani navig softwar
globu place excelsiu system hospit use competit implant opportun grow implant share institut spine
case repres revenu globu gener estim complex deform case may procedur valu well-abov
dollar amount straightforward degen case might dollar add fairli quickli high volum institut
page
globu medic matter stock item excelsiusgp still runway
strh thought think begin
north american spine societi nass annual meet globu showcas new imag system final stage develop
expect approv avail sale second half mani spine compani chosen partner imag
compani though globu take differ approach develop imag technolog in-hous industri contact commonli
suggest o-arm technolog industri standard improv upon think globu abl find synergist
opportun robot system new imag platform
addit compani hasnt discuss next-gener system featur expect next layer excelsiu system includ
augment realiti capabl research sever compani recent hire found one vp-level execut background motion
track mix realiti tie sever patent one own globu medic
patent detail augment realiti surgic system includ head mount
display hmd see-through display screen motion sensor camera
anatom model use patient data creat medic imag equip rotat
scale least portion three dimension anatom model base
rel locat orient refer marker rotat least
portion three dimension model base head motion signal track
measur movement hmd rotat scale three dimension anatom
model display display screen
difficult quantifi new featur determin whether featur
would either add-on exist system could manifest next-gener
robot system perhap launch time shortli imag system
though compani clearli listen surgeon custom continu
prove engin innov capabl abl scale
come year expect compani continu innov excelsiu
launch addit applic featur globu indic launch
robot system second half larg joint remain unclear whether
add-on applic new system launch
bottom line think there
excelsiusgp meet eye
augment realiti could real
potenti next-gener platform
page
globu medic matter stock item globu maintain industry-lead margin profil
strh thought ye think concern overdon
expect globu maintain low- mid- adjust ebitda margin profil next sever year model adjust ebitda
in-lin estim believ sever item weigh metric recent year
first compani alreadi invest substanti enabl technolog product develop least sinc januari
globu acquir origin excelsiu technolog beyond excelsiusgp system compani also recent showcas new imag system
yet fda clear built intern therefor like took sever year develop manag indic continu
spend enabl technolog segment develop larg joint robot system sens compani alreadi fairli far
develop pathway system well compani confid commerci launch therefor expect see
signific hike current level
second globu need continu hire sale repres trauma divis that realli new point time
know compani least dedic employe trauma segment sale repres sale leadership role
accord linkedin rep hire last year think compani continu hire time trauma tend
geograph divers typic requir sizeabl sale presenc dont think acceler materi addit
globu experi hire scale specialti sale team without materi impact oper margin industri sourc includ
sale repres surgeon contact publicly-trad privat compani suggest globu effect built capit sale team even
excelsiusgp system approv hire salari employe expens clearli well-manag compani
call materi late earli believ capit rep like transit commission-sel point
time time increment revenu given fact robot yet clear compani essenti ate cost
sale repres probabl million million annual cost
globu said invest trauma inr imag navig robot busi basi point drag ebitda
third quarter therefor exclud headwind compani ebitda margin would upper rang nearli
nearli unheard spine/orthoped
globu need launch imag system though expect leverag exist inr sale forc need build larg joint sale
team support robot launch howev think compani redeploy spend today area busi long-term
also think potenti margin pressur could off-set part better implant price expect globu abl show synergist capabl
robot implant order valid better price
bottom line think compani continu invest busi seem investor concern margin
compress current level dont think case
page
august
presid ceo
evp
david demski serv presid ceo
globu sinc august
compani sinc incept mr demski join
globu origin cfo held posit
time transit role
presid chief oper offic
compani mr demski led domest
manufactur financ
mr demski transit lead
compani expans area imag
navig robot along orthoped
trauma presid emerg technolog mr
demski well-known well-respect within
surgeon commun proven tactic
strateg leader newest role
scavilla serv evp chief
current role mr scavilla svp
cfo globu join may mr
scavilla brought uniqu strateg perspect
prior role cfo believ strateg
skillset oper expertis transit
well new expand role
prior join globu mr scavilla spent almost
year variou financi manag
cfo global vice-president financ busi
oper jnj vision divis ww
vice-president financ advanc steril
product divis
david paul found globu led
compani chief execut offic
august transit
role execut chairman prior globu mr
paul held sever posit synth
recent serv director product
patent patent applic
name mr paul recogn
inventor product develop
engin expertis distinctli instil
globu compani cultur
svp cfo
keith pfeil newest member globu
medic execut team join
compani cfo august
prior join globu mr pfeil spent
year publicly-
trade consum product compani
recent serv evp cfo css
respons financi plan
analysi intern audit investor relat
svp gener counsel corpor secretari
kelli huller serv svp gener counsel
corpor secretari sinc decemb
compani sinc
prior current role ms huller held variou
legal role globu includ vice-president associ
gener counsel director legal affair
join globu ms huller trial attorney
conrad obrien repres public
privat compani area commerci
employ product liabil malpractic
annual perform bonu determin
healthquest capit
svp global hr
plant manag oliv healthcar
vice-president hires/departur captur linkedin last month
compani file linkedin
hire new area
vice-president sale total joint arthroplasti
came thale
presid surgimap
vice-president corpor account strateg price
vice-president sale south central us
came
came
nation sale director spine tokyo
came zimmer biomet
page
compani report strh estim
page
initi buy pt
page
appli multipl sale estim deriv pt in-lin median med-tech high growth
forward top-lin growth peer group buy-rat share
si joint fusion market continu develop expect due reimburs headwind inabl chang physician
mindset unforeseen challeng
competit dynam materi chang larger diversifi player refocus market
unforeseen neg chang reimburs coverag payment rate ifus competit products/altern
commerci misstep compani grow sale forc clinic specialist team rapid pace
lack profit
page
scenariobear casestrhbul deceler low-teen revenu growth multipl contract in-lin slower-growth peersassum usd/ldd product gain matur rep revenu acceler rang contribut multipl expansionassum ldd product gain matur rep revenu acceler rang contribut multipl expans modestli peer groupupsid vs current healthcar
found medic devic compani pioneer use new minim invas
implant system ifus treat sacroiliac joint dysfunct million american adult estim
chronic lower back pain publish clinic studi shown chronic pain
could associ sacroiliac joint current avail non-surg manag option
medic therapeut inject radio-frequ ablat often temporari solut histor open
surgeri option invas unproven result
si-bon ifus system procedurally-integr solut includ patent triangular implant insert
minimally-invas approach ilium sacrum typic three implant
insert ifus si joint procedur implant place rigid shape titanium
construct help stabil joint allevi pain bone fuse
beyond develop manufactur implant essenti single-handedli built
minimally-invas sacroiliac joint fusion market year develop effort reimburs expertis
grow special sale forc arsen clinic data publish clinic
studies/pap random trial data outcom ifus foundat clinic support
rare spine true competit advantag compar altern treatment sinc first
introduc compani ifus technolog use procedur
surgeon howev ifus remain low-single-digit penetr unit state
indic intent offer best-in-class platform sacro-pelv solut develop
core adjac market time includ adult deform market
major revenu
come unit state
revenu come sale ifus
relat tool instrument
compani file strh estim
page
sacrum sit base spine connect iliac bone major bone pelvi two
sacroiliac joint sacroiliac joint largest human bodi help support weight
upper bodi posit upright time weight upper bodi put stress joint
may wear cartilag around joint cartilag wear small movement si joint
begin caus sever pain lower back and/or buttock
diagnos si joint pain difficult surgeon gener perform seri provoc test around
joint better pinpoint pain come inject anesthet sacroiliac joint
fluoroscop guidanc local anesthet reduc pain physician confirm
sacroiliac joint sourc pain
lifestyl chang medic manag
howev gener non-surg manag allevi pain temporarili fix revers
progress diseas therefor major patient ultim requir surgic intervent
open si joint fusion procedur surgeon make sizeabl inch incis use plate
screw fuse joint howev today si joint fusion procedur done minimally-invas
incis inch less minut surgeon drill iliac bone across si joint
sacrum creat channel surgic implant channel creat surgeon impact
broach fit implant channel gener three implant use per procedur depend
size patient
fusion immedi stabil joint typic result reduct pain shortli procedur
time bone grow implant perman fuse joint
page
last decad essenti single-handedli built minimally-invas sacroiliac joint fusion market develop effort
reimburs expertis arsen clinic data grow special sale forc believ compani ifus technolog
tip point broader adopt break numer barrier see substanti opportun ahead believ
address opportun billion market suggest market still low-single-digit penetr believ compani
durabl grow higher next year beyond core opportun view bedrock essenti therefor call option
valuat think could meaning halo effect ifus busi
si joint fusion market larg attract opportun estim total address market si joint fusion
approxim billion though patient treat si-joint fusion today uphil battl develop market
infrastructur success manag build strong foundat clinic evid grow reimburs coverag physician
payment rate togeth drive awar acknowledg si joint part chronic lower back pain problem
increas use minimally-invas surgic solut solut heavi lift seem done though continu posit payor
decis come month along steadily-improv physician incent awar drive penetr overal
ifus remain under-penetrated today revenu estim million assum compani low-single-digit
penetr today studi shown patent triangular design significantli reduc si joint pain versu non-surg altern
ifuse-specif data result exclus reimburs coverag decis rariti medic devic privat payor
grow spent signific amount time develop market infrastructur spent last month invest grow
commerci team support broader adopt market awar ifus system compani commerci team
individu made equal-part direct sale repres clinic support specialist expect expand commerci footprint
support acceler revenu growth profil next sever year growth
beyond core opportun believ bedrock techniqu adult deform could meaning halo effect core
busi size potenti opportun least million like million importantli note si-bon exist
call point overlap directli deform surgeon call point reason expect could halo effect surgeon begin perform
bedrock techniqu find valu si joint solut well
page
page
matter stock item big address market drive broader adopt
strh thought estim sever key driver broader adopt
estim total address market si joint fusion billion includ nearli patient annual
patient treat today si fusion headwind drive broader adopt market howev think
opportun exist simpli take time grow surgeon payor accept
take low-end conserv though largest
retrospect studi suggest reason
si joint clinic trial
compani file strh estim
estim deriv histor literatur though support approach note current million si inject
year estim patient receiv multipl non-surg steroid inject sacroiliac joint pain highlight
fact exist patient popul activ seek receiv form treatment year controversi around
size market today though view even market grow half larg think compani would still
msd penetr base estim
page
us patient lower back patient lower back patient si joint patient si joint patient elig patient elig year elig patient sij address popul estim million healthcar
matter stock item big address market drive broader adopt
strh thought estim sever key driver broader adopt
key driver market growth view improv physician incent treat patient popul minimally-invas
surgic altern continu momentum reimburs coverag increas number total cover live
what histori
physician bill si-joint fusion procedur
categori code distinguish
open minimally-invas case
american medic associ ama
establish new categori code specif
consist obtain reimburs perform procedur
temporari code experienc materi
deceler growth time period
temporari code surgeon unabl
minim invas percutan si
si fusion case reimburs
use establish categori
code specif
whether procedur open
code minim invas
ama establish new categori code
specif minim invas percutan si joint fusion
though payment rate almost half rate compar
open fusion case
rate payment increas
remain rel stagnant sinc howev announc
earli novemb payment rate effect
januari increas nearli shown exhibit
expect increment payment help
drive surgeon adopt minimally-invas fusion technolog
page
matter stock item big address market drive broader adopt
strh thought estim sever key driver broader adopt
key driver market growth view improv physician incent treat patient popul minimally-invas
surgic altern continu momentum reimburs coverag increas number total cover live
what histori
categori code first put place mani non-
coverag decis place privat payor year si-bon
built strong foundat reimburs coverag nearli
doubl number total cover live million
million two year addit commerci
payer exclus cover ifus triangular implant exclus
coverag rariti medic devic requir strong clinic
evid behind technolog
mid-decemb fourth largest commerci health plan
 anoth million cover live establish posit
coverag polici minim invas si joint fusion polici
exclus fda clear implant place across si joint
intend promot fusion
despit substanti progress sever larg commerci
payor collect cover nearli million live still
posit coverag polici minim invas si joint fusion polici
decis gener review payor least year
often time frequent influenc public
long-term clinic data societi support
difficult time potenti posit coverag decis list
sever largest insur along cover live
time last review anticip time next review
publish si-bon result long-term prospect
studi call loi long term outcom insit sifi
recent publish septemb show continu durabl
outcom si joint fusion use ifus implant believ
long-term clinic efficaci help grow payor support
 payor unfavor
bottom line realiz there skeptic around size market opportun compani still lsd penetr today
lot new develop reimburs front give confid market growth
page
matter stock item sale forc expans acceler growth
strh thought confid
much focu stori market infrastructur compani invest grow sale forc recent year
total direct sale repres commerci team employe direct rep clinic specialist
addit broader reimburs coverag physician payment increas believ surgeon train accept import driver
direct sale repres addit tie revenu growth hire clinic specialist support direct sale team drive
higher revenu per direct sale repres time track hire direct sale repres plan end
year total direct sale repres nearli one year ago addit believ compani doubl size
clinic specialist team year clinic specialist end clinic specialist end
total si-bon plan end commerci team total repres clinic specialist
meaning increas total field rep compani end
today estim matur direct sale repres gener million million annual revenu
long-term expect matur sale repres abl grow averag product million annual revenu base
abil drive deeper penetr within exist account support clinic specialist abil activ grow new account
 sale repres end abl gener million annual revenu would repres million sale
time substanti sale estim million
grow sale forc
faster rate
compani
spine market base
si bone
find
bottom line si-bon substanti expand direct sale last year may take time fulli contribut
confid compani abil acceler revenu growth
page
end yeara ofend growth midpoint healthcar
matter stock item deform contribut growth
strh thought think call option point could acceler growth current level
spine procedur includ deform trauma case perform mani
surgeon gener well-reimburs procedur deform case requir
fusion surgeri mani patient present multi-level
degen diseas may also present si joint pain futur surgeon
abl recogn diagnos si joint anoth sourc pain he/sh may
abl treat patient si joint fusion either larger deform case
multilevel fusion year treat adult spinal deform
half case extend sacrum histor deform
surgeon use iliac screw alar iliac screw bottom
construct adult deform procedur howev screw loosen and/or
break time impact outcom procedur
ifus bedrock techniqu allow surgeon place one ifus implant
side sacrum posterior approach three implant side
later approach conjunct multi-level spine fusion earli
biomechan test data compani shown addit ifus
bedrock reduc si joint motion screw alon therefor
think bedrock techniqu support better fusion sacroiliac joint
base spine ultim better foundat long construct
fourth quarter fda clear ifus bedrock techniqu
use patient si joint dysfunct undergo adult
deform procedur accord compani exist indic use
april compani receiv addit clearanc fda expand
indic long construct procedur
appear little/no revenu bedrock includ consensu
estim view product essenti call option point time
compani could penetr even potenti case assum
averag procedur valu per case rang
bedrock could repres increment revenu lift revenu
growth rang
market expand later procedur increas
market given higher averag implant used/cas
compani file transcript strh estim
even small penetr market opportun matter
fulli number today
bottom line deform essenti call option
point potenti lift growth
rang time
page
posteriortot muli-level multi-level fusion extend multi-level fusion extend number implant total healthcar
presid ceo
april
may
juli
annual perform bonu determin
sever corpor goal well individu
mr dunn serv presid ceo
chairman sinc compani incept april
prior join mr dunn ceo
replac small bone fusion compani
decemb april compani
sale wright medic
inbon mr dunn held sever ceo
executive-level posit technolog industri
recent ceo activ decis softwar
servic busi sold knova
softwar mr dunn well-respect
experi persist bring high-growth
uniqu technolog market
ms franci join origin cfo may
given ad titl august
prior join ms franci held sever cfo
posit recent serv
cfo auxogyn inc women health compani
decemb septemb
auxogyn ms franci vice-president financ
cfo treasur promega corpor life
scienc reagent compani septemb
decemb prior promega ms franci
cfo bruker bioscienc publicly-trad life scienc
instrument compani march
septemb held sever
addit offic posit privately-held compani
prior join mr recupero
presid catalyst perform advisor llc
advis medic devic compani
catalyst mr recupero spent year
baxano origin join compani vice-president
sale market recent serv
presid ceo compani
acquisit june
mr recupero also spent year kyphon
serv vice-president sale octob
decemb
addit role mr recupero held
sever sale manag role own
consult group
gener counsel
august
vice-president medic
april
vice-president market access reimburs
mr pisetski join origin director
legal march promot
current role august join
mr pisetski practic law privat serv
gener counsel new wave surgic corpor
mark properti inc amongst medic
technolog healthcar servic compani
addit spent sever year cooley llp
repres variou compani medic
technolog biotechnolog healthcar servic
dr reckl join origin vice-president medic
affair given ad titl februari
join dr reckl spine
surgeon spine center loveland colorado
wyom center spine orthoped surgeri
cheyenn wyom associ orthoped surgeri
cheyenn wyom ramsey hospit
clinic st paul minnesota
think surgeon voic execut team
especi high-growth compani build new
market good strateg decis compani
join dr yerbi vice-president
prome inc medic suppli compani june
januari prome dr yerbi
spent year sit board sever non-
profit compani june may dr
yerbi vice-president st franci medic
technolog spine compani acquir
kyphon
st franci spent sever year
director experiment biomechan palo alto
vice-president hires/departur captur linkedin last month
compani file linkedin
page
compani report strh estim
page
deep dive spinal cord stimulation- market background
page
deep dive market background
 what happen us market last decad
estim us market grew mid-singl digit innov space lack
transform improv product launch larg iter develop market leader boston scientif
abbott/st jude
introduc senza system unit state catalyz acceler overal market growth
steadi cadenc new product introduct space player thereaft us market grew
size estim compound-annual-growth-rate nearli time period revenu
base expand
sinc debut histor slow-to-innov player follow lead attempt mitig share loss
steadi cadenc new system introduct time player evolv platform enhanc made
waveform modal patient manag option next-gener system includ abbott proclaim/prodigi
wavewrit intelli evolv workflow omnia
notabl think sever new system specif allow competitor
slow share loss begin gain share time share shift away abbott view
lag introduc transform product improv bog salesforc turnov specif within
busi
estim us market declin modestli larg due y/i comp custom destock associ certain
high-volum product order pair dearth innov product launch well modest asp degrad
note start show sign market recoveri deliv y/i growth quarter
compar declin y/i growth first half year due progress compani commerci
appendix detail review supplement inform procedur market
page
deep dive market background
 what happen us market last decad
page
deep dive market background
 us market go
think market reacceler growth remain strong weak
expect world-wide market grow high singl digit next sever year
view growth fuel improv patient experi associ use sub-percept sub-percept
plu paresthesia therapi grow awar opioid overus indic expans beyond tradit back leg pain relief
 repres total market today estim forecast grow high singl digit
next sever year
establish market current domin larger capit compani includ abbott share
estim share share share greater resources/capac maintain
protect market share us
estim market slow think prime reacceler us sever
focu non-opioid altern pain manag light opioid epidem us recent strengthen tailwind
expect continu go forward given recent emerg opioid epidem us subsequ polit societ
support opioid reduc obviat technolog
increas competit player within market drive innov altern modalities/waveform new product launch
page
deep dive market background
page
 revenu ww revenuesboston market shareww market shareboston underli growth ratesww underli growth rate adj fx boston healthcar
initi buy pt
page
appli multipl sale estim deriv pt roughli premium median med-tech mid cap peer group
buy-rat share
inabl shift physician adopt away current tradit therapi
heighten competit direct indirect prove impact expect
sale forc turnov lead unpredict quarterli revenu
increment reimburs cut may pressur price longer term
page
scenariobear casestrhbul organ revenu growth hsd rang multipl contractsassum organ growth ldd rang multipl expandsassum organ acceler hdd multipl expandsupsid vs current healthcar
global medic devic manufactur focus treat chronic pain neuromodul
platform offer patient paresthesia-fre altern tradit spinal cord stimul use treat
lower back leg pain receiv ce mark approv enter us market
catalyz sleepi domest ww market absent transform new
technolog introduct platform acceler market growth high teen
grow domest market share us market estim
today compani sell three system senza system first system deliv proprietari
therapi senza ii launch smaller refin footprint advanc batteri
system allow year life recent senza omnia launch novemb
deliv proprietari therapi addit avail frequenc
beyond offer lower back limb pain compani sight set appli technolog
peripher diabet neuropathi pdn segment current larg control pharmacolog treatment
compani revenu growth gross margin profil
page
product platform technolog
proclaim elit
launch us
launch us
freedom
launch us
page
follow entranc us market introduct proprietari patent-protect paresthesia-fre altern tradit
grown share domest market estim compani innov awok
once-sleepi market catalyz reacceler overal market growth high-teen compani experienc grow pain
primarili tie sale forc turnov aggress sales-ori compani cultur growth flatten new ceo took helm
began implement turnaround strategi stand today think compani pois regain market share next year
robust clinic data stabil realign commerci infrastructur key new product introduct drive penetr exist market back
 leg pain addit think growth augment market expans opportun includ pain peripher diabet neuropathi
pdn non-surg refractori virgin back pain
market still under-penetrated think growth reacceler like overal macro tailwind opioid epidem
us expect market continu seek new solut chronic pain move away opioid use subsequ abus addit
believ new product launch space includ senza omnia first system design deliv pair frequenc
hz allow greater option surgeon physician peace-of-mind versatil treat individu patient
requir time also believ physician continu expand treatment lower back pain market beyond tradit scss core
compet address lower leg pain
think begin regain share captur histor commerci challeng real turnaround effort
believ compani pois grow market rate take time stabil sale team linkedin analysi show
compani sale forc grown mid-singl digit last month addit believ compani inventory-rel headwind
rear-view mirror enter expect introduct omnia platform allow rep opportun re-engag
physician account offer physician versatil encompass system support option waveform deliveri
clinic superior technolog histor headwind unlik effect new tailwind support potenti growth acceler
think compani could grow full year world-wide howev new manag team proven
conserv guidanc approach therefor would surpris see conserv guidanc street current model low-
there like beyond bread butter beyond compani offer tradit expect leverag
technolog adjac market opportun includ pain pdn take time requir expans exist call-point pdn
estim million patient opportun us addit compani continu explor valu technolog use non-surg
refractori virgin back pain though data import market segment
page
matter stock item key driver growth
order confid go-forward growth rate import understand compani abl achiev impress
histor top-lin growth market share captur sinc receiv ce mark approv fda approv senza system
compani grown revenu base ww sale take market share less year
estim compani outsiz growth driven number factor includ
superior label clinic efficaci data proprietari technolog
new compel technolog sluggish market
technolog focus patient comfort paresthesia-fre
recent year competitor launch new product space incorpor option differ waveforms/mod expect stori
hing compani commerci execut measur success turnaround effort though item remain
import driver near long-term growth
senza-rct studi first head-to-head trial space publish anesthesiolog octob compar senza
therapi tradit tonic therapi use boston scientif precis platform trial demonstr statist signific
sustain superior therapi tradit primari back primari leg pain
pain patient primari leg pain patient respond treatment achiev greater reduct
report va score compar patient paresthesia-bas control group addit patient receiv
therapi experienc reduct mean leg pain va compar tradit therapi
back pain patient primari back pain patient respond treatment achiev greater reduct
pain accord va score compar patient paresthesia-bas control group furthermor patient
receiv nevro stimul experienc mean reduct back pain va score compar tradit therapi
given lack clinic efficaci date util histor technolog treat primarili back pain still view data
expans opportun overal market
addit studi demonstr patient prefer paresthesia-fre base technolog patient control group
paresthesia-bas report uncomfort stimul compar nevro senza devic true paresthesia-fre technolog
beyond clinic superior platform tradit leg back pain technolog offer true paresthesia-fre
base technolog util anatom lead placement compar tradit complex time-consum paresthesia-bas
map order place lead
paresthesia-bas map requir physician repeatedli wake patient placement determin ensur proper paresthesia
placement coverag lead nevro technolog util anatom lead placement sinc technolog use paresthesia
reduc variabl physician procedur time
page
matter stock item key driver growth
chronic back leg pain senza-rct studi
found compar tradit
patient see
reduct
back pain reduct va score
pain reduct va score
reduct pain
patient retain
page
matter stock item key driver growth
see reacceler share gain alongsid grow market go forward
current model reacceler growth high-single-digit rang go
forward us market
new ceo helm stabil reinvigor commerci team think
grow quickli overal market go forward owe
improv commerci execut realign refocus
sale team new sale rep onboard practic begin
contribut revenu
continu uptak due proven clinic superior
platform technolog support omnia launch
tradit slow-to-innov compani introduc new
product past stave share loss reacceler top-lin
growth profil think dd growth spurt remain short-liv
time market shift support clinic data superior claim
even compar sub-percept base technolog also
intend improv patient experi think clinic profil
note competitor call point across product offer diversifi
benefit limit success compani act
sole provid product case remain focus pure-play
market weve seen allow tactic approach market
notabl think recent perform third quarter indic return
momentum growth trial perman implant us
indic potenti reacceler market trial typic lead
perman implant month think compani fourth quarter
impli growth guidanc could prove conserv think double-digit
growth could achiev importantli net prior-year stock
current-year de-stock organ sale growth third quarter would
nvro clinic efficaci back leg pain still remain
superior even light new competitor sub-percept
page
matter stock item key driver growth
omnia launch add fuel nvro growth
began commerci senza omnia platform us novemb follow larg qualit quantit market analysi
new ceo done better understand market segment growth drivers/opportun
omnia round compani offer includ system frequenc waveform versatil recent studi player
space shown patient prefer platform option customiz therapi addit omnia allow expand
offer patient physician hesit implant patient devic singl waveform offer
front-end omnia platform provid physician new programm patient new remot allow easier
program altern waveform omnia system support frequenc abil pair
frequenc waveform togeth enabl dual mechan action
back-end nevrocloud support abil track outcom patient physician practic order better
understand use technolog
market larg concentr four major player new product innov still drive share shift market
exampl launch intelli system estim compani growth recov high-single-
digit declin nearli y/i growth full-year post-launch
similarli launch boston scientif wavewrit system drove compani averag growth mid-single-digit
full-year post launch
new product addit space stabil drove acceler top-lin growth
share gain came expens abbott expens deceler time-frame
us estim grew market share within two year launch exit
market share howev full year subsequ competitor product launch share gain slow materi
compani captur total share gain full year
expect omnia help drive share gain though import compani commerci
execut continu sale forc stabil see addit omnia platform bag opportun rep re-
engag physician account challeng year offer physician versatil all-encompass system support clinic
page
matter stock item key driver growth
new commerci effort correct histor misstep begin show sign improv quickli greater extent
manag initi expect chang within sale structur larg work meaning chang
expect sale rep think leverag like within model
field physician sale repres relationship import grow account util sale repres need
present surgic procedur reason sale repres hire import lead indic growth
believ experienc above-averag attrit direct us sale forc estim believ attribut
histor aggress selling-focus cultur misalign focu attrit part led flat year-over-year growth
therefor sale forc stabil improv commerci execut key prioriti compani lead
growth improv
direct new ceo keith grossman appoint role march compani realign entir global
commerci team newly-appoint chief commerci offic compani focus improv cross-funct
align begin see earli sign improv think continu
sale forc focu also misalign recent histori sale repres appropri incentiv drive convers
trial implant perman implant per manag commentari issu pin-point incent realign think
fundament growth improv third quarter saw inflect point growth trial implant growth acceler
y/i compar basi
destock longer factor
follow appoint compani new ceo manag opin market dynam lead flat year year growth
cite inconsist execut leadership sale front high sale turnov rate misalign sale incent led high volum
discount order place toward end quarter lack rep focu patient trial ultim perman implant
physician work overstock underutil inventori place market experienc deceler overal growth
third quarter destock larg complet reason think compani guidanc could prove
conserv current fiscal guidanc mid-point compani guidanc rang impli y/i growth quarter
howev think compani abl exceed estim given easier year-over-year growth comparison growth
pair absenc destock headwind histor stronger year-end growth strong trial implant growth
histor lead indic subsequ quarter growth
page
matter stock item happen market growth
strh thought think reacceler
reacceler hsd growth go forward
estim us market lsd growth perspect
market whole digest high-teen growth seen past
work inventori destock tie aggress sale practic addit
lack new product introduct believ limit overal
growth look forward think market growth prime reacceler
maintain hsd growth driven sever underli
focu non-opioid altern pain manag
new innov product launch altern modalities/waveform
addit think market remain under-penetrated see continu
market expans reacceler growth support hsd growth includ
better deliveri modal support continu penetr use leg
better deliveri modal support expans back pain
efficaci prior senza-rct limit
better clinic efficaci overal new system respond rate vs
devic histor focus treat predominantli chronic leg pain given
efficaci leg vs back pain said superior nvro data
senza-rct studi support use technolog patient lower back
pain thu see market expans opportun technolog
thu far think advanc waveform focus improv patient
experi includ sub-perception/paresthesia-fre technolog option
waveform continu drive growth sector
sub-perception/paresthesia-fre technolog shown prefer
patient senza-rct studi patient receiv tradit
tonic stimul report uncomfort stimul compar
receiv paresthesia-fre stimul furthermor bsx whisper
trial patient prefer sub-percept compar
reduct mg opioid intak
patient receiv
well reduct patient receiv
reduct
patient opioid
number
patient
page
matter stock item futur catalyst pdn
market expand opportun peripher diabet neuropathi near fruition
beyond compani current core busi growth spinal cord stimul market treat lower back leg pain compani plan
expand neuro modul offer pain peripher diabet neuropathi pdn market
compani current estim roughli patient us medic manag sever pain due diabet neuropathi
estim half patient fail treatment therefor total estim pdn us patient popul
current us guidelin lyrica first-lin treatment manag pdn contain potenti advers effect
drowsi dizzi lead withdraw long-term use accord review rct data publish
diabet therapi februari
base analysi literatur clinic demonstr statist signific efficaci certain dose lyrica pregabalin
compar placebo group month patient experienc reduct va score compar
tradit devic variat within clinic trial patient popul rate efficaci rel in-lin
reduct lower back leg pain howev percentag patient experienc reduct va score
demonstr trial lyrica less seen senza-rct publish anesthesiolog octob
leg pain patient experienc reduct va score compar
lyrica trial patient popul differ trial thu directli compar
pdn studi began enrol fulli enrol compani intend present preliminari
data north american neuromodul societi nan annual meet januari
compani expect fulli launch follow present data depend insur provid pdn
may alreadi label garner payment given peripher pain alreadi includ indic howev reimburs prove
challeng expect compani use support label claim pdn work directli payor standard
reimburs specif around pdn indic
initi subset treat pdn present nan show reduct va scale earli
small popul think initi data promis posit clinic data full studi would allow compani
expand offer addit divers market
page
matter stock item futur catalyst pdn
beyond pdn complet pilot studi sever addit pain area think repres compel opportun howev new
area like requir robust clinic valid market develop effort reason think continu focu right-
size ship core busi develop pdn market focu materi turn indic today compani
pipelin indic includ
addit long term think compani potenti move treatment continuum care less invas option
surgic back patient given rel sub-par outcom surgic intervent back pain need repeat procedur
compani on-going non-surg refractori back pain trial support fda approv howev difficult predict potenti
reimburs coverag dynam system ultim receiv approv payor may argu therapi mask pain
could surgic treat
per clinicaltri gov nsrbp trial estim random chronic refractori back pain without leg pain
consid candid spine surgeri either therapi convent medic manag trial expect primari
complet date june data expect earli
sham-control trial lower back pain trial tradit modulate-lbp
sham-control rct high-frequ spinal cord stimul chronic neuropath back pain
uk base studi random either intervent sham control follow
studi began enrol august expect complet august
moreov given paresthesia-fre deliveri nvro pain reliev stimul compani opportun run sham control studi
technolog to-dat yet complet given paresthesia-bas technolog think could better posit compani
gener clinic data sham control data tend carri higher clinic valu given abil random noth especi
subject market pain toler ultim drive market expans area lower back pain
near-term compani recent began launch omnia platform us novemb plan bring product ce mark
countri well australia
head-to-head trial burstdr back pain
per clinicaltri gov stanford univers current run random open label trial util open-sourc learn healthcar
system collabor health outcom inform registri choir investig effect burstdr improv pain
function patient chronic back and/or leg pain trial began enrol august expect primari complet
decemb think trial would demonstr key efficaci data two novel waveform current edg
burstdr think time primari data collect analyz present like full studi
patient publish estim competit two player like would shift away primari efficaci
like may incorpor efficaci altern waveforms/mod well slightli diversifi away core chronic leg back pain
page
matter stock item futur catalyst pdn
va visual analog scale subject measur acut chronic pain
page
presid ceo
keith grossman serv presid ceo
sinc march mr grossman also
chairman compani board mr
grossman held sever execut posit
year experi medic
devic field recent second
time presid ceo thoratec
long career mr grossman led
period strateg chang deliv
growth gener valu sharehold
andrew galligan serv cfo
sinc june mr galligan would retir
current role cfo announc third
quarter result mr galligan would remain cfo
compani appoint
successor also serv transit role
period thereaft
prior mr galligan serv cfo
consum electron manufactur
niamh pellegrini new member
execut team join compani
june ms pellegrini year
experi healthcar industri
prior join ms pellegrini vice
presid global oper abbott
vascular respons drive
billion revenu
michael carter serv vice presid
global sale nevro sinc join compani
prior join mr carter held sever
commerci gener manag leadership
posit recent vice
presid gener manag stryker spine
annual perform bonu determin
sever corpor goal well individu object
revenu gross margin target
vice-president hires/departur captur linkedin last month
compani file linkedin
david caraway serv chief medic
offic sinc current role mr
caraway provid strateg direct support
design develop adopt
therapi aim advanc neuromodul
field also share respons
gener provid medic scientif
evid product
prior mr caraway ceo
center pain relief tri-stat mr
caraway held variou leadership posit
year medic practic north
american neuromodul american societi
intervent pain physician
vice-president research
christof christofor serv vice
presid research develop
prior join mr christofor serv
vice presid qualiti engin thoratec
corpor oversaw compani
oper design supplier function mr
christofor held variou leadership
manageri posit year thoratec
corpor unit state surgic
chairman ceo
presid ceo
current sit two board
sr complianc corpor counsel
counsel coheru bioscienc
current chief commerci offic viewray
page
compani report strh estim
page
page
initi buy pt
page
appli price-to-earnings multipl discount median med-tech larg cap peer group ep estim deriv
pt buy-rat share
unexpect slowdown core end market includ larg joint neg impact compani target weighted-averag market growth
rate revenu growth
competit core end market either larg establish healthcar compani new smaller competit entrant differenti
technolog impact abil regain market share price pressur
product launch includ rosa robot system gain traction market underwhelm versu expect
suppli disrupt remedi progress execut issu impact zimmer biomet abil regain market share
achiev sustain msd organ growth
page
scenariobear casestrhbul flat top-lin growth modest declin oper margin price-to-earnings multipl contract lsd top-lin growth assum oper margin essenti flat modest improv price-to-earnings multipl expans still discount peer includ sykassum lsd top-lin growth gm expans price-to-earnings multipl expans in-lin peer group discount sykupsid vs current healthcar
zimmer biomet global leader musculoskelet space billion world-wide
revenu zimmer found acquir bristol-my spun-off
individu publicly-trad compani earli zimmer announc would acquir biomet
billion emerg one largest orthoped compani world
major revenu come sale product sold large-joint hip/kne
procedur though compani also design manufactur sell comprehens list product
sport medicin extrem trauma spine craniomaxillofaci thorac dental procedur
compani offer broad orthoped offer strong brand recognit allow zimmer act
partner hospit time vendor consolid
addit zimmer biomet global presenc diversifi revenu base
revenu come intern market compani oper countri world-wide
sell product countri
compani file strh estim
compani bucket revenu six categori includ
knee revenu
hip revenu
 revenu
spine craniomaxillofaci thorac revenu
dental revenu
less revenu
note set includ product sold surgic sport medicin extrem foot ankl
page
new manag took helm zimmer biomet decemb compani implement two-year turnaround plan
reinvigor growth turn corner two-year mark growth slowli sure recov model low-singl digit
revenu growth acceler current level think histor headwind relat manufactur constraint
product suppli prove major constraint growth go forward zimmer biomet begin return low-singl eventu mid-
singl digit growth expect focu shift bottom-lin see sever lever pull drive earn growth margin
expans compani abil drive revenu acceler pair earn expans drive multipl expans stock
despit out-performance full year compar still trade steep discount
turnaround stori materi histor headwind relat manufactur constraint suppli level recent year
impact compani abil achiev low-single-digit revenu growth quarter reason believ revenu growth could
higher second part year model call growth give credit signific invest compani
made recent year turnaround busi manag portfolio organ sinc bryan hansen took helm new manag
brought board compani fulli transpar turnaround process transform hasnt happen
overnight progress in-lin ahead expect
revenu growth acceler current level believ zimmer biomet growth profil improv compani
achiev low singl digit growth order achiev mid-singl digit growth higher think compani need see sustain recoveri
larg joint busi like augment newly-launch robot system and/or see higher contribut segment busi
higher-growth end market either one item could help drive revenu growth improv current consensu estim
difficult specul time inorgan tuck-in activ addit portfolio manag believ manag may choos
incorpor strategi time augment current growth rate
compani achiev low-singl digit revenu growth think translat mid- high-singl digit earn growth appear
street model effect oper leverag next year modest improv expect earn growth primarili driven
financi leverag versu oper leverag though think could bring substanti margin improv addit think
enough lever pull compani hit beat earn project year follow
page
presid ceo
zimmer
spun-off
bryan hanson appoint
global launch persona
launch vanguard
robot
fda clearanc
biomet
issu suppli
dental larg
page
zimmer biomet matter stock item compani return mid-single-digit revenu growth
strh thought think
zimmer company-specif challeng recent year due part dis-synergi disrupt encount
merger biomet manufactur issu exasper qualiti issu impact compani abil produc
adequ suppli disrupt associ merger fairli straightforward combin two orthoped giant result
sell dis-synergi simpli weigh perform bit longer anticip compani suppli issu requir bit
zimmer biomet first merg becam clear combin entiti could manufactur adequ product fulfil demand
conting plan place ensur suppli could meet demand sale repres unabl fulfil order
led perpetu back order custom issu late fda inspect zimmer biomet north campu manufactur facil
warsaw indiana issu observ uncommon med-tech cite condit may constitut
violat food drug cosmet fd act relat act compani encourag address respond
observ april zimmer receiv relat north campu facil respond fda august
zimmer receiv warn letter fda cite outstand qualiti issu facil compani sought
address issu manufactur qualiti remedi effort suppli product neg impact addit
compani need priorit resolut manufactur issu simpli took time invest away prioriti
believ compani abl grow least line weighted-averag market growth rate estim next
coupl year today revenu tie hip knee market gener grow low-singl digit rang
year compani invest robot platform goal abl reviv larg joint busi invest
area higher growth potenti set end market growth rate mid upper singl digit
page
market sizemarket sharemarket growth compani present octob market size share estimateszimm biomet healthcar
zimmer biomet matter stock item dont robot system
strh thought ye consensu expect knee growth still seem low
zimmer biomet lose market share knee busi recent year part
compani impact before-ment suppli constraint relat
qualiti remedi effort howev also believ zimmer innov engin
slow time frankli focu requir elsewher
time period competitor name abl launch new
product taken market share histor fairli sticki market
importantli compani launch mako total knee applic earli
year zimmer biomet acquir rosa robot platform origin
applic rosa spine compani develop platform offer
total knee applic compani show system proto-typ american
academi orthoped surgeon aao annual meet receiv clearanc
rosa knee system januari
rosa knee featur pre-op plan tool real-tim intraop data
soft-tissu bone anatomi design improv bone cut accuraci rang
motion gap analysi potenti improv flexion restor natur joint
earli launch process compani place hand system
thu far seem plenti runway zimmer biomet grow robot presenc
exist zimmer account oppos fight robot share competit
account addit estim procedur done robot today
therefor still tremend opportun zimmer success
grow market expect zimmer price system rang
fairli wide rang well see launch progress ultim
think compani benefit implant pull-through surgeon begin grow
util system
zimmer biomet revenu come knee busi therefor
import compani regain least share-neutr posit certainli think
robot launch help point time consensu model knee
growth next year
page
zimmer biomet matter stock item what earn potenti next sever year
strh thought think earn growth acceler next sever year
street expect zimmer biomet earn target essenti stagnant last month sit
next year impli earn growth consensu sit consensu
major earn growth near-term like driven financi leverag rather oper leverag point
consensu oper margin estim essenti flat improv declin weve seen recent histori call
moder improv
expect gross margin soft potenti year-over-year due higher cost good sold tie current ineffici
improv inventori turn system though consensu alreadi model case think dynam well understood point
price pressur consist estim basi point headwind gross margin though price headwind noth new orthoped
gener off-set mix improv
think consensu expect set appropri think target unrealist given
compani deliv oper margin low rang histor begin show leverag particularli
compani acceler revenu growth rate
compani report factset
page
factset gross oper margin estimateszimm biomet healthcar
presid ceo
evp cfo
bryan hanson serv presid ceo
zimmer biomet sinc decemb mr
hanson held sever execut posit
career strong track record
lead grow global medic devic
prior zimmer biomet mr hanson serv
member execut committe execut
vice presid group presid
therapi group busi mr
hanson oversaw provid strateg direct
billion invas therapi busi
suketu upadhyay newest member
zimmer biomet execut team join
compani execut vice presid
cfo juli
prior join zimmer biomet mr upadhyay
spent year bristol-my squibb
recent serv svp global financi
oper mr upadhyay held sever
financi leadership role year
career healthcar industri
coleman lannum serv senior vice
presid investor relat zimmer biomet
sinc march mr lannum respons
consult execut manag
sharehold investor commun
mr lannum year investor
relat experi healthcar
industri recent serv svp
investor strategi investor relat
offic mallinckrodt pharmaceut
svp global qualiti regulatori
group presid global busi
svp global oper logist
april
mr tripp serv svp global
oper logist sinc april
prior join mr tripp serv svp
manufactur
cardin work vice-president
oper patient monitor
recoveri busi mr tripp retir
 navi navi reserv year
servic
david kunz serv svp global qualiti
regulatori affair zimmer biomet sinc
april compani sinc
mr kunz also chair compani qualiti
mr kunz join zimmer biomet origin vice-president
regulatori affair qualiti assur
spine divis held posit
time transit role svp global
qualiti regulatori affair prior zimmer mr
kunz serv vice presid qualiti
ivan torno serv group presid
orthoped zimmer biomet sinc
novemb current role mr torno
respons compani orthoped
group includ joint sport
extrem trauma busi well
america region
prior zimmer mr torno serv
variou global role fortun
compani recent world-wide
presid global urolog medic
critic divis becton dickinson
incent tie adjust ep consolid adjust oper profit consolid
constant currenc revenu consolid free cash flow execut
annual perform bonu determin
incent tie region adjust oper profit region constant currenc revenu
region free cash flow apac emea execut
prsu tie constant currenc revenu growth rel total sharehold return
compar index constitu compani
execut chairman board hospira
ceo prior hospira
mr begley spent nearli year abbott
held senior leadership posit
retir includ presid
ceo consum prior ms
bernard held leadership role sever global
current presid ceo inc
join found gkb global
serv ceo unitedhealthcar
current ceo resm inc risen
variou leadership role sinc
chairman wellpoint inc inc
ceo
svp cfo posit
retir
ceo presid board member assertio
recent ms hilado serv evp cfo
allergan retir
svp presid asia pacif emea em
thermo fisher scientif sinc rise
variou leadership posit within
compani sinc join
mr michelson current senior advisori
kkr manag sinc
member kkr manag llc prior
page
compani report strh estim
page
initi buy pt
page
appli multipl sale estim deriv pt repres premium averag med-tech
high growth forward top-lin growth peer group buy-rat share
competit core end market either larg establish healthcar compani new smaller competit entrant differenti
technolog impact abil regain market share price pressur
concentr end-market lead quarterli fluctuat disrupt procedur slowdown key account
acquisition/integr risk vilex inorgan transact compani continu diversifi offer
page
scenariobear casestrhbul organ revenu growth slow multipl contractsassum organ growth continu low rang multipl expand modestlyassum organ growth return rang multipl expandsupsid vs current healthcar
orthopediatr found categori leader pediatr orthoped surgeri market
subset orthoped market larg neglect industri larger diversifi
orthoped compani cater specif pediatr end-market instead tend focu
sizeabl adult opportun therefor histor pediatr orthoped surgeon would improvis
treat children make-shift adult orthoped solut child anatomi gener much
smaller size grow often complex uniqu challeng specif pediatr physiolog
adult implant caus harm help case
orthopediatr design manufactur sell comprehens portfolio implant solut
tailor children primarili focus three largest area pediatr orthoped market
trauma deform complex spine scoliosi sport medicin procedur today
compani offer broadest pediatric-specif orthoped product offer commercially-
avail surgic system time focus effort develop relationship
pediatr surgeon societi cater product develop categori invest
market develop includ clinic educ global sale organ exclus focus
compani indic intent grow pipelin organ acquisit
end announc acquisit vilex june expand compani
trauma deform portfolio includ extern fixat system orthex proprietari x-ray plan
compani file strh estim
major revenu today sold
sale agenc unit
state also sell
revenu intern
direct sale agenc stock
distributor global sale organ
exclus focus pediatr orthoped
page
orthopediatr public compani almost two year stock essenti tripl time-frame compar
period manag team proven abil execut target strategi underappreci segment
orthoped market peg compani total market opportun world-wide think focu deep commit clinic
educ surgeon relationship field continu drive organ revenu growth next sever year addit believ
orthex deal great strateg addit portfolio could materi contributor compani growth profil come
year base proprietari assess limb lengthen research societi llr member base believ limb-lengthen surgeon
fairli concentr specif area therefor expect abl extend new market fairli easili
halo effect broader busi support potenti acceler revenu come year
orthopediatr recogn leader pediatr orthoped market offer comprehens portfolio implant solut
tailor children use procedur character unambigu clinic need limit reimburs pushback peg market
billion world-wide would suggest still less penetr today pediatr orthoped market underserv
larger diversifi orthoped compani cater specif end market instead focu sizeabl adult opportun
orthopediatr focus effort develop relationship pediatr orthoped surgeon train global sale organ
market segment importantli pediatr orthoped surgeon specialist therefor case opportun sale
repres cross-sel within portfolio
compani abl consist deliv organ revenu growth street model growth deceler
assum organ growth essenti in-lin expect compani like take conserv approach
guidanc recent year see reason growth could maintain potenti acceler current level base
higher level instrument set invest sale forc expans recent year
orthex deal great recent addit june acquir compani name vilex vilex primarili foot ankl
surgeri compani sell solut pediatr adult though made clear intent divest and/or licens adult
product line maintain exclus focu pediatr applic go forward flagship pediatr product orthex hexapod deform correct
extern fixat system proprietari x-ray plan softwar like deal fill product gap compani trauma deform
segment expand surgeon reach limb reconstruct specialist treat pediatr patient beyond children hospit concentr
certain area orthex gener million revenu think product could least million
page
grow quickli
enter
scoliosi
market
acl
expand
launch
wrist
spine surgeri
launch
page
orthopediatr matter stock item top-lin growth durabl
strh thought think invest instrument set remain key driver
street model growth deceler impli organ growth essenti in-lin expect
compani like take conserv approach guidanc recent year see reason growth could maintain
potenti acceler current level base higher level instrument set invest sale forc expans weve seen
one driver histor compani growth abil invest instrument set orthopediatr typic place instrument set
potenti hospit custom gener revenu sale hardwar implant use instrument
compani went public somewhat capit constrain unabl invest new instrument set prospect custom pre-ipo
compani deploy million instrument set invest averag year use proce ipo octob
compani increas invest deploy instrument set million track invest million million
full year typic take month instrument set reach full util therefor think million increment
sale includ vilex model million million reason target compani hasnt
comment think like continu grow invest instrument set give confid abil
achiev consensu estim call growth
relat sale forc expand sale forc recent year domest sale agenc employ nearli
focus sale repres start grow sale team support implant growth tie higher util
instrument set field today well new instrument set placement pair new product launch recent come month
think compani grow organ revenu
page
revenu million healthcar
orthopediatr matter stock item compani sustain competit advantag
strh thought bear thesi time hasnt materi dont think
orthopediatr design develop commerci orthoped implant three
largest categori pediatr market trauma deform complex spine sport
adult orthoped surgeon gener special specif subset adult
orthoped market spine trauma sport medicin pediatr surgeon train
simpli focu children therefor pediatr orthoped surgeon typic generalist
commonli complet addit often extens subspecialti educ
treat broader set orthoped issu spine trauma sport medicin
trauma deform largest segment busi mani injuri
treat conserv method cast though case surgic
intervent requir trauma deform procedur pediatr patient includ
simpl fractur broken bone complex fractur sever break caus damag
multipl bone soft tissu tendon ligament and/or joint nonunion malunion
bone heal properli heal wrong posit bone infect and/or
complex spine common spinal deform scoliosi sideway
curvatur spine treatment option depend sever condit though
spinal case often overlook condit worsen conserv treatment
may longer option surgic treatment requir spinal implant includ
pedicl screw rod may use help correct curv
sport medicin procedur small portion revenu less
repres import categori grow market opportun procedur
segment includ anterior cruciat ligament acl reconstruct procedur
reconstruct medial patellofemor ligament mpfl ligament reconstruct
procedur pediatr surgeon may replac acl mpfl surgic tissu graft
goal restor function
time compani discuss develop new gener adjust implant
system call activ grow implant smart implant address specif
clinic need patient early-onset scoliosi limb length discrep
compani file strh estim
page
orthopediatr matter stock item compani sustain competit advantag
strh thought bear thesi time hasnt materi dont think
sizabl divers orthoped compani focu offer solut tailor pediatr segment market
compani target pediatr segment orthoped believ real opportun convert physician use bulki make-shift adult
implant patient-specif pediatr solut
trauma deform estim johnson johnson stryker major pediatr implant market today howev
larg focus either maintain grow presenc adult trauma market estim billion world-wide compar
million pediatr market orthopediatr current own high-singl low-doubl digit share market today expect
share continu grow physician convert patient-specif offer categori
complex spine bit competit gener speak though johnson johnson medtron half market
estim tailor solut pediatr pediatr market estim million compar broader
complex spine categori billion estim
sport medicin compani offer solut specif design pediatr patient
penetr opportun expect abl continu develop market
note larger compani orthoped market consider resourc avail could feasibl develop sale
product develop infrastructur focu pediatr end-market howev believ order success compani would need build
full product offer across three categori address need pediatr orthoped surgeon believ compani without direct
overlap three market trauma complex spine sport medicin would unlik build pediatric-specif product portfolio today
would requir signific invest develop portfolio product new area littl adult presenc today
johnson johnson stryker top-four presenc trauma complex spine sport medicin even two market leader would
unlik view sacrific focu sizeabl adult opportun and/or build salesforc call pediatr hospit
page
arthroscopy/soft tissu repairspinetraumaarthrexmedtronicdepuy traumasmith nephewdepuy synthesstrykerdepuy synthesstrykerzimm biometstrykernuvasivesmith nephewlead select orthoped market healthcar
orthopediatr matter stock item vilex orthex contribut meaning revenu
strh thought ye big market work suggest call point concentr
june acquir vilex foot ankl surgeri
compani sell solut pediatr adult orthopediatr
made clear intent divest and/or licens adult product line
maintain exclus focu pediatr applic go forward like
deal fill product gap compani trauma deform
segment expand surgeon reach limb reconstruct specialist
treat pediatr patient beyond children hospit
flagship pediatr product orthex hexapod deform correct
extern fixat system proprietari x-ray plan softwar orthex
use treat pediatr congenit deform limb length discrep
system includ hardwar compon easili
calibr strut infection-reduc hydroxy-apatit coat pin
patent point click softwar softwar develop founder
vilex abraham lavi phd dr dror paley founder paley
institut west palm beach florida dr paley well-known respect
pediatr surgeon commun believ also one largest
consult nuvas special orthoped base open payment
data current user precis nail
vilex deal open million global market opportun
orthopediatr estim therefor increas size
compani market opportun importantli allow
compani broaden portfolio offer product address
trauma deform address market
model million revenu orthex grow
million reach penetr market
opportun compani abl deliv orthex estim
would need deliv growth core busi order hit
estim in-lin consensu think achiev
like beatabl goal compani
page
orthopediatr matter stock item vilex orthex contribut meaning revenu
strh thought ye big market work suggest call point concentr
like deal fill product gap compani trauma deform segment expand surgeon reach limb
reconstruct specialist treat pediatr patient beyond children hospit
pediatr surgeon commun highli concentr major procedur done less hospit
pediatr surgeon unit state comparison total member american academi orthoped surgeon
across orthoped specialti
manag indic surgeon unit state use orthex system today surgeon
limit interact date acquir vilex orthex sold team distributor field sale
repres though sens vilex sale forc focus pediatr opportun
limb lengthen reconstruct societi list member websit includ surgeon unit state
websit list member state found surgeon highli concentr texa member surgeon list
texa therefor believ call point requir substanti expans sale forc headcount offer uniqu synergi
limb lengthen reconstruct societi llr websit strh research
page
presid ceo
mark throdahl serv presid
ceo sinc join
compani januari prior
orthopediatr mr throdahl group
presid zimmer world leader
mr throdahl bring vast experi
orthopediatr serv oper
execut domest intern
field medic devic diagnost
fred hite serv cfo
orthopediatr sinc join compani
prior mr hite spent
year symmetri medic publicly-
trade medic devic compani
recent serv cfo investor relat
offic symmetri tenur
symmetri compani went public
complet secondari offer made
david bailey
sinc compani found
recent mr bailey look intern
sale distribut oper product
develop execut vice presid
prior mr bailey work
sale repres smith nephew
orthopaed year
gener counsel vice-president legal hr
evp commerci
gerritzen serv gener counsel
 vice-president legal hr sinc
join compani mr gerritzen
respons provid legal advic
counsel compani also serv
compani secretari mr
gerritzen bring vast experi across
focus product liabil busi
prior mr gerritzen work
partner bingham greenbaum doll llp
dr peter armstrong serv chief
medic offic sinc join
compani januari
prior dr armstrong held
sever posit shriner hospit
children recent serv chief
vice-president hires/departur captur linkedin last month
compani file linkedin
greg odl held sever leadership posit
sinc join compani
recent execut vice
presid commerci evp
commerci mr odl look
domest sell organ market
prior mr odl held sever
posit smith nephew recent
serv district manag indiana
hauser serv vice presid trauma
 deform correct
prior mr hauser held
variou leadership role djo global
biomet zimmer mr hauser
year experi medic devic
vice-president educ train
region vice-president sale
current vice-president sale conventu orthopaed
annual perform bonu determin
achiev corporate/strateg
page
compani report strh estim
page
deep dive cardiac monitor
page
deep dive cardiac monitor market background
accord center diseas control prevent cdc approxim million patient unit state heart rhythm
disord arrhythmia arrhythmia present irregular often rapid quivering/flutt heartbeat manifest sever form
tachycardia occur heart beat fast beat per minut lead syncop faint blood clot lead
stroke and/or heart attack heart failur hf sudden death
bradycardia occur heart beat slow less beat per minut also lead syncop hf sudden death
depend sever durat condit
atrial fibril af quiver irregular heartbeat common manifest heart arrhythmia af affect
american accord aha typic life threaten af often carri increas risk heart failur clot format stroke
af blood pool heart chamber form blood clot blood clot form within left atrium left upper chamber
break away travel brain caus blockag arteri feed blood brain known ischem stroke
hospit death occur annual us due af accord nation stroke associ addit
estim ischem stroke occur annual us roughli attribut af
ambulatori ecg use instrument diagnosi af estim roughli one-third patient live af
experi symptom patient consid asymptomat silent af estim roughli af-rel
stroke present patient asymptomat af detect time stroke demonstr framingham studi
publish stroke septemb
defin caus type arrhythmia often result structur heart issu includ coronari arteri diseas high
blood pressur valv disord chang heart muscl cardiomyopathi medic condit
arrhythmia diagnosi import identif abnorm heart rhythm earli allow physician interven administ
treatment ahead potenti life threaten condit stroke hf sudden death includ use medic invas devic
defibril pacemak what estim stroke patient af prevent earlier detect
intervent accord
limit arrhythmia detect electro cardiogram ecg histor use identifi patient irregular heart rhythm
physician offic howev given sudden transient present heart arrhythmia ecg often limit diagnost abil
miss event occur outsid physician offic extend ecg monitor outsid physician offic devic abl collect
continu data longer observ period increas diagnost yield devic continu record data extend period
time shown increas likelihood arrhythmia detect demonstr retrospect analysi patient continu
monitor saw detect arrhythmia occur beyond tradit monitor period
page
deep dive cardiac monitor market background
us patient heart rhythm disord arrhythmia
us patient atrial fibril af
annual outpati arrhythmia test us ambulatori ecg
top-lin growth driven new segment
page
total marketcagrambulatori wear cardiac healthcar
deep dive cardiac monitor market background
macro tailwind pair newer disruptor space drive market growth
histor option cardiac monitor proven burdensom hospit servic perspect limit innov
relat devic patient tradit requir wear bulki wire-bas monitor shown rel low diagnost
yield think innov cardiac monitor devic servic tie abil use patient analyt data better detect
arrhythmia prevent relat issu give hospit comfort outsourc servic grow overal market opportun greater
appreci long-term monitor ultim provid better experi outcom patient
standard ambulatori cardiac monitor equip histor requir up-front capit purchas hospit includ tradit
holter monitor worn patient hour steril reus anoth patient reason hospit may
limit number tradit holter monitor onhand therefor limit number patient treat given time hospit also
typic insourc cardiac monitor capabl tradit holter monitor though cardiac monitor place signific time burden
hospit staff
addit tradit ambulatori cardiac monitor limit diagnost abil larg result limit wear time
hour poor patient complianc due bulki wire-bas technolog lack continu monitor case patient
requir activ monitor capabl captur small window arrhythmia
accur diagnosi arrhythmia specif af import patient af five time like develop stroke
without af accord american heart associ given graviti lost product associ cost healthcar
industri us annual estim aha think product servic cardiac monitor segment need
clinic data demonstr reduct stroke risk support broader adopt reimburs
page
deep dive cardiac monitor market background
macro tailwind pair newer disruptor space drive market growth
expect awar valu longer-wear option arrhythmia detect includ mcot devic extended-wear monitor
devic continu drive modest growth overal ambulatori ecg market importantli think combin devic innov
pair servic capabl well proven abil better diagnos arrhythmia better complet data lead
hospit comfort outsourc cardiac monitor patient treat time fashion believ innov space
market expand rise tide lift boat space newer smarter devic patient-friendli form factor
well proprietari algorithm improv diagnost yield ultim abil improv patient outcom displac tradit
devic still repres lion share space
look forward current model high-singl digit growth mcot devic high-teen growth extended-wear monitor
still plenti room novel technolog drive market expans share captur symptomat a-fib patient
asymptomat silent af also repres significantli larger patient popul long-term market expans opportun compani
space patient could benefit asymptomat cardiac monitor base inclus criteria mstop studi
recent demonstr encourag data hr accord irhythm manag team specif accord
framingham studi publish stroke atrial fibril relat stroke case asymptomat thu detect
time stroke demonstr valu earlier diagnosi could provid asymptomat patient popul said believ meaning
penetr otherwis unidentifi untreat patient popul year given need suffici clinic data gener
 present follow mstop expect present hr need sway physician interest adopt
establish support societ guidelin reimburs ultim adopt question referral/pati treatment
pathway proactiv screen af patient think burden clinic proof especi regard fals notif rate
associ econom benefit type technolog key think investig step made thu far remain promis
ultim take development effort payor provid healthcar compani
page
deep dive cardiac monitor market background
arrhythmia symptom
first-lin ecg
longer time period
requir gener
ecg inform
monitor period
sensat
short breath
physician offic
devic
amount time
activ pass
heart
amount electr
heart
page
deep dive cardiac monitor market background
ambulatori ecg devic monitor patient annual us expect grow low-single-digit next five year physician
typic initi prescrib first-lin tradit holter monitor outpati monitor requir physician isnt abl diagnos patient
in-offic rest ecg read prescrib second-lin devic event monitor extend wear monitor mcot implant cardiac
monitor base multitud factor weigh anticip wear time diagnost yield overal cost recent year introduct
newer at-hom patch-bas continu monitor altern tradit holter monitor patient complianc increas patient may take
tradit devic sleep exercis shower etc ultim increas diagnost yield lower cost devic higher diagnost yield
annual monitor
first-lin arrhythmia detect therapi given low price medicar patient
typic monitor patient day continu monitor patient ecg analysi done retrospect patient upload data
devic flash drive analysi short wear time often caus devic miss event occur less frequent may occur
devic bulki clip belt electrod directli connect chest seri wire data retrospect analyz
monitor patient short period
quick take histor gold standard physician known largest sharehold market first line diagnost test larg
growth replac newer holter devic longer wear time higher diagnost yield higher price
annual monitor
second-lin therapi alongsid mcot limit memori store trace arrhythm event non-continu
activ patient begin record data usual transmit via telephon devic incorpor automat record
capabl abnorm rhythm detect
worn rel low diagnost yield price
page
deep dive cardiac monitor market background
annual monitor
second-lin therapi improv tradit ecg monitor system ad real-tim commun
technician evalu valuabl situat ecg data may help physician react urgent arrhythmia
syncop portion af symptom patient and/or tradit first-lin devic unabl detect
arrhythmia prescrib wear-tim hour tradit holter monitor extern event
work typic reserv patient infrequ symptom
mcot diagnost yield rel high price
annual monitor
worn week continu monitor record ecg data gather wear time
provid physician summari format use complet no-real time commun import
patient requir urgent treatment
significantli better data captur diagnost yield shorter-term devic also carri slightli higher
annual monitor
implant ecg devic last provid much longer window arrhythmia
detect patient infrequ symptom
use today primarili syncop cryptogen stroke post-af ablat
procedur high cost high diagnost yield
page
deep dive cardiac monitor market background
diagnost yield vs monitor ambulatori ecg devic
overview ambulatori ecg devic characterist rank order
price hc system typic reimburs rate
page
product categorytyp wear periodextend monitoringuniqu featurespati considerationsdiagnost yieldpric hc systemtradit dayscontinuousshort term provid quantit data arrhythmia burden low extern loop event monthev correl symptom even brief arrhythmia record brief period timemay requir patient trigger extend wear monitor weekscontinuousintermedi term provid continu data week improv patient complianc due avoid lead wirespatch view comfort expos water brief shower submerg water patch caus skin mcotup monthev time central monitor alarm continu record detect event result real-tim commun physician longer monitor time higher cost rel extern optionsrequir cell phone size monitor carri patient monitor see healthcar
deep dive cardiac monitor market background
model unit estim per categori base
histor commentari market particip
see rough estim given lack definit
market data addit use data
medicar physician fee schedul servic count
calibr estim histor mcot growth
us estim
ambulatori ecg includ roughli
zioxt make largest share
beat epatch cardiokey make
assum growth overal ecg market
driven favor demograph increas
awar ambulatori ecg util less well-
us ambulatori ecg market model growth forecast segment devic
page
total wear cardiac growth ambulatori wear cardiac totalambulatori wear cardiac healthcar
deep dive cardiac monitor market background
product introduct drive shift diagnosi paradigm
recent introduct patch base technolog extend wear
monitor well mcot space materi began take
share ambulatori ecg monitor market given higher complianc rate
diagnost yield repres growth driver compani special
industri outlin next page
expect patch-bas altern extend wear monitor
servic market sustain double-digit unit growth continu eat
tradit holter market first line diagnost tool also expect newer
entrant mcot field primarili zioat gain traction mcot
space though also expect mid-singl high-singl digit growth continu
mcot field consist histor growth rate advanc
space drive expans second-lin diagnost tool
ambulatori ecg market see factor expand extend
wear monitor share
see share gain first line treatment space drive tradit
holter share event monitor share
respect
addit think growth mcot space
continu materi grow share second-lin diagnost tool
current model hsd growth mcot devic
anticip expand share
appendix detail review product cardiac monitor segment
patch base ambulatori ecg monitor grown share
patch base form factor shown improv
patient comfort complianc ultim improv upon
think time valu proposit continu
take share tradit ecg monitor
page
initi buy pt
page
appli multipl compar select med-tech peer group ebitda estim deriv pt
buy-rat share
deceler deterior patch base ecg market growth specif mcot includ signific chang
competit dynam newer entrant mcot space irhythm zioat deriv major revenu
well inabl take share extended-wear space compet irhythm market-lead zioxt
product launch includ epatch mct patch gain traction market underwhelm vs expect
integr geneva acquisit gain traction market and/or caus relat disrupt compani core
neg effect recent cybersecur disrupt compani core busi well perceiv threat go
page
scenariobear casestrhbul organ revenu growth slow ebitda compress multipl contractsassum organ growth ldd ebitda margin expand low rang multipl holdsassum organ growth ldd ebitda expand low rang multipl expand modestlyupsid vs current healthcar
incorpor cardionet inc intent transform tradit
holter monitor market offer long-term real-tim monitor capabl option
partner hospit outsourc cardiac monitor arrhythmia detect servic
compani introduc first mobil cardiac outpati telemetri mcot devic open first
cardiac monitor center today remain largest player mcot space
market repres entir ambulatori ecg monitor test
perform annual us estim
origin establish premium player mcot space sinc
expand offer beyond mcot includ broad portfolio ambulatori electrocardiogram
ecg monitor devic servic inorgan tuck-in includ tradit holter
monitor extended-wear cardiac monitor event monitor pacemak intern normal
ratio monitor addit compani leverag robust portfolio solut offer
research capabl recent extend offer includ data manag
software-solut acquisit geneva health solut
compani bucket revenu three categori includ
healthcar biotel heart includ diagnost cardiac monitor offer
mcot event tradit holter extended-wear cardiac monitor pacemak inr monitor
revenu
research biotel research includ central servic core laboratori provid
cardiac monitor imag servic scientif consult data manag drug
medic devic trial healthcar product revenu
corpor biotel biotel allianc oper busi brand focus
sale manufactur engin develop non-invas cardiac monitor
popul health manag devic diabet manag revenu
page
page
sinc pioneer mcot market scale organ acquisit strengthen leadership posit
wireless medicin believ stock perform hing compani abil continu drive meaning market growth legaci
product broader adopt mcot technolog servic on-going product launch allow greater exposur faster-growth sub-
segment ambulatori ecg market includ extended-wear market integr execut market develop
commerci implant cardiac monitor softwar platform acquir geneva health acquisit ultim coalesc
factor drive top-lin growth adjust ebitda expans go forward
mcot growth strong expect continu estim mcot busi deliv robust upper-singl digit
growth sinc think still room take share tradit ecg monitor patient infrequ symptom
specif patient af symptom smaller market syncop cryptogen stroke post-af ablat newer base patch
technolog augment strong underli market growth believ establish share mcot space instal base reimburs
coverag servic orient infrastructur robust product offer recent patch-bas product launch protect compani market share
though think new competit segment prove market-expans time
ebitda stabil expans beyond lifewatch integr expand share mcot
space entir ambulatori ecg market respect drive synergi line
think contribut still steam left new product launch mcot space mcot patch focus patient comfort complianc
trend well thu far led higher same-stor growth believ new product introduct allow leverag within opex line allow
rep go deeper cardio monitor space slight gross margin contribut benefit expect geneva healthcar solut
acquisit add revenu bottom-lin geneva contribut modestli ebitda margin
tradit softwar gross margin oper margin synergi drive addit contribut
geneva acquisit compel though still earli day recent acquisit geneva health march acquir
cloud-bas softwar platform consolid independ manag variou manufactur implant monitor devic implant loop
record pacemak icd singl platform streamlin physician workflow within cardiolog practic common pain point allow
physician focu time patient think could take time develop market physician transit away exist
softwar track platform think deal make strateg sens open larg opportun unit state could lend cushion
ebitda estim
page
matter stock item robust mcot growth go forward
strh thought think continu grow hsd rang
today base busi concentr higher-growth mcot space
biotelemetri mcot busi made nearli total revenu base segment declin percentag revenu
drop roughli total sale due addit recently-acquir geneva healthcar well growth extend monitor
expect mcot busi remain materi contributor go forward
histor biotelemetri mcot busi come volatil though recent trend shown stabl revenu growth contribut
estim biotelemetri mcot busi enjoy healthi growth wave novel technolog began take signific
share ambulatori ecg market larg control tradit holter event monitor support stabl price
estim organ mcot volum declin meaning cumul basi due
commerci insur refus pay non-contract mcot servic lead implement conserv prior-
author polici effect reduc number mcot unit sold patient whose insur would pay servic
econom downturn like impact growth estim total mcot price paid patient cover servic
medicar reimburs declin like neg impact growth payment rate paid declin
estim mcot volum grew organ compound-annual-growth-rate acceler stabl
reimburs environ driven market develop effort well extend synergi lifewatch
page
matter stock item robust mcot growth go forward
strh thought think continu grow hsd rang
addit player mcot space drive market expans
octob publicly-trad launch new devic servic zioat support patient may elig
mcot devic though think opportun one player mcot market irhythm formid competitor
given compani success thu far extend monitor zioxt platform see multipl factor protect
biotelemetri exist market share near-term includ
like take time new mcot devic includ payer contract alreadi highlight irhythm
first quarter confer call
payer landscap market segment remain challeng measur number health plan neg coverag polici technolog
percentag plan narrow set indic use rel higher bar medic necess includ fail first-lin test ceo kevin king earn call
recent launch patch-bas mcot mcot patch allow compani maintain foothold mcot space
offer new patient-friendli form factor exist mcot account believ beat exist account base sticki
like retain main supplier
think patient wear mcot requir service-ori experi real-tim monitor though irhythm certainli
capabl develop servic time
page
market share wear cardiac unit categori tradit wear cardiac healthcar
matter stock item adjust ebitda trend come year
strh thought expect continu expand
beyond steadi revenu growth believ ebitda margin
continu expand shown exhibit right
stock price appreci gener tie adjust ebitda growth
diversifi portfolio offer past
significantli lifewatch acquisit driven
primarili oper synergi adjust ebitda
increas basi point full
year current model adjust ebitda
time period share
begin peak end compar
time-frame ebitda growth slow
mcot growth drop y/i ldd hsd first half
year rebound ldd growth sinc begin
share pull back rebound
sinc return dd mcot growth number factor
driven stock price perform recent year find tie
think follow key tenant support stabil
continu expans ebitda margin go forward
continu benefit lifewatch integr strength mcot
grow exposur high-growth extended-wear market
drive synergi top-lin support ebitda expans
geneva acquisit still earli stage believ
synergi exist given businesss gross margin profil
current model adjust ebitda expans
larg driven
conserv estim materi benefit geneva
acquisit lesser extent expans extended-wear
acceler
past year beat share price larg trade direct
ebitda expans slow adjust ebitda growth
outsiz drag share perform
page
matter stock item adjust ebitda trend come year
strh thought expect continu expand
driver ebitda expans includ
continu benefit lifewatch integr leverag within cardio-focus offer expand market
juli close acquisit lifewatch time largest competitor us mcot market
paid stock cash ev sale
annual period estim acquisit lifewatch driven basi point oper
margin expans continu support expans compani end third quarter oper margin
compar third quarter
oper margin expans driven primarili oper synergi salesforc integr a/opex streamlin
cog benefit think still room continu improv margin front
expect favor product mix benefit lifewatch deal payer mix continu support steadi improv gross margin go
expans extended-wear monitor market
extended-wear busi current repres compani total revenu expect grow
driven compani continu launch patch base extended-wear monitor epatch
compani seen acceler same-stor growth follow new product launch expect continu roll-out extended-wear
monitor well new product mcot space continu benefit margin
addit expect compani leverag larg instal base monthli profess repres
healthcar revenu drive margin expans new premium product support gross margin well drive top-lin revenu growth
present competit advantag compani begin materi invest launch extend wear product
think like come perman code establish
close acquisit geneva health solut first quarter expect leverag exist instal base
shift revenu stream histor hardwar servic busi includ recur softwar busi offer physician singl port
cloud-bas platform remot monitor patient implant cardiac devic pacemak defibril loop record
think continu revenu synergi associ geneva acquisit expect deal contribut gross margin
near-term given margin profil tradit softwar busi
page
matter stock item expans data manag
march close acquisit geneva health solut cloud-bas softwar platform consolid independ
manag variou manufactur implant monitor devic implant loop record pacemak icd singl platform
streamlin physician workflow within cardiolog practic common pain point allow physician focu time patient
acquir compani up-front consider addit performance-bas earn out less
compani intend integr geneva platform exist data analysis/alert system provid one-stop shop
cardiolog practic busi model built redirect reimburs remot monitor away individu cardiolog practic
geneva think like regard loss leader given limit scale compani current expect revenu
doubl repres contribut model contribut grow
third quarter call entir direct healthcar sale team salespeopl train geneva
platform compani alreadi start target largest/highest valu exist account addit
process expand geneva dedic specialist end end
strateg sens think acquisit geneva make sens expand offer includ broader offer
ambulatori cardiac monitor solut specif deal offer exposur ilr market compani sell ecg except ilr manag
ilr platform drive synergi within core busi top-lin well line
near-term think import consid broader adopt technolog requir market develop may take time given
compani need transit user platform larg integr direct-to-physician hardwar compon one reli
princip softwar offer manag guid sale rep target largest/highest valu account like would requir
rigor integr process given size account amount user would need transit new system
moreov think quarterli revenu within busi may remain lumpi near-term thu may see manag abil guid
quarterli basi slightli impair howev think time lead predict smooth revenu stream given
monthli bill cycl inher busi model said think long-term acquisit abil drive immens valu
address market initi integr physician account thu far deliv increas physician revenu better patient care
due higher complianc rate better effici hospit system
page
member bod
gener counsel svp
mr capper serv presid ceo
sinc prior mr
capper serv presid chief offic
member bod diabet manag
prior role diagnost mr caper
serv presid ceo medic inc
privat medic suppli provid diabet wound
care respir therapeut categori
ms getz join compani may previous
held posit vice presid financ
prior ms getz serv vice presid
financ specialti
pharmaceut compani april may
variou financi leadership role viasi
healthcar healthcar technolog compani acquir
cardin juli march april
mr ferola join februari
come year experi busi
manag legal affair corpor
prior join mr ferola serv
vice-president gener counsel secretari nipro
diagnost formerli diagnost inc
overlap ceo joseph
capper also preivous serv corpor
secur attorney greenberg traurig llp
wilworth paxson llp addit
work execut manag role
american stock exchang list compani
dr wadhawa join part
acquisit geneva health solut dr wadhwa
current serv practic cardiologist
cardiac electrophysiologist san diego ca dr
wadhwa receiv medic degre state
univers toma jefferson medic colleg
train intern medicin gener cardiolog
thoma jefferson univers philadelphia pa
advanc fellowship cardiac electrophysiolog
univers california san diego
dr wadhwa prviousli serv advisori board
biotronik st jude
medic sanofi-aventi fellow heart
mr raher appoint svp hr conjunct
acquisit lifewatch servic
prior work lifewatch mr raher held sever
senior human resourc role
telecommun began career johnson
johnson hold sever posit consum
pharmaceutical/chem well corpor
mr broadway name presid biotel
heart compani largest divis account
compani revenu report
busi
mr broadway join june
vice presid market bring
sale market experi promot
senior vice presid market septemb
becam senior vice presid sale
market januari work
mr broadway serv director
market
june focus commerci novel
therapi treatment stroke prevent atrial
director consult deliveri cgi
vice-president qualiti regulatori
vice-president regulatori affair qualiti assur
none linkedin
annual perform bonu determin
revenu growth target ebitda growth
vice-president hires/departur captur linkedin last month
compani file linkedin
page
compani report strh estim
page
initi buy pt
page
appli multipl sale estim deriv pt repres discount median med-tech high growth
yr forward top-lin growth peer group buy-rat share
upcom chang zioxt reimburs transit temporari code perman code
affect largest sourc revenu
competit dynam newer entrant extended-wear market specif biotelemetri epatch
irhythm deriv major revenu
product launch includ zioat gain traction market underwhelm vs expect
expans asymptomat af space materi soon current model market
develop identif patient requir invest current model
page
scenariobear casestrhbul organ revenu growth slow multipl contract organ growth multipl expand organ acceler mid rang multipl expand vs current healthcar
irhythm medic devic digit healthcar compani focus detect monitor abnorm heart
irhythm design first wire-fre patch-bas wearabl bio-sensor use help physician monitor ultim
diagnos patient cardiac arrhythmia view compani patient-friendli form factor pair reliabl
data-driven servic solut address histor shortcom tradit holter monitor sinc launch
compani zio platform use one million patient aggreg data approxim
hundr million hour curat heart beat data use drive refin proprietari arrhythmia detect
recent compani expand offer includ zioat mobil cardiac telemetri mcot solut
patient requir real-tim monitoring/commun long-term expect compani leverag
establish base cardiac monitor extend domest asymptomat silent af market estim
includ ten million potenti patient
valu patient
patch-bas design improv patient complianc compar tradit bulki
devic devic worn continu exercis shower sleep
lead improv diagnost yield
studi publish american journal medicin januari found
patient prefer zio monitor tradit holter monitor
valu provid
technician irhythm cms-certifi independ diagnost test facil idtf
analyz gener easy-to-read action digit report deliv physician
help diagnos patient streamlin clinic workflow
valu payor
compar mobil cardiac monitor devic holter event record mcot
ilr zio servic offer higher yield low cost solut view
page
irhythm redefin way cardiac arrhythmia clinic diagnos combin patient-friendli patch-bas wearabl bio-sensor cloud-bas data
analyt machine-learn capabl compani catalyz paradigm shift ambulatori ecg monitor patient risk arrhythmia zio
servic platform includ proprietari databas artifici intellig inform system layer wearabl form factor collect refer compani
four-lay stack time think irhythm proprietari offer grow standard care first-lin treatment outpati cardiac monitor
bring streamlin physician workflow improv patient outcom ultim better econom within healthcar system patient requir real-
time monitor howev new technolog compani run controversi reimburs narr find place market
indic transit temporari code perman categori code outsiz investor concern transit
could lead materi cut reimburs payment could impact privat payer rate ultim irhythm revenu scenario analysi suggest
downsid risk may alreadi contempl stock point addit sever new product introduct could off-set potenti reimbursement-ti weak
may suggest concern revenu slow-down overdon
expect compani deliv sustain forward top-lin compound-annual-growth-rate driven clinic support behind zio servic along market
develop effort commerci execut prospect random control trial rct real world experi irhythm gener
robust clinic portfolio support higher diagnost yield demonstr need analysi certain patient beyond tradit first-lin holter monitor
period addit strong clinic data compani commerci execut driven top-lin growth annual rep product improv even
compani continu on-board new sale rep expect annual rep product continu trend higher vs peak product
driven increas penetr exist account product mix shift toward higher pay direct-bil fix contract payor addit believ
product augment compani recent oct full commerci launch zioat solut averag price higher
zioxt
reimburs remain overhang stock analyz potenti outcom past pend updat compani reimburs
rate set overhang stock compani transit temporari code perman code given irhythm bill
directli cardiac monitor servic specif technic compon believ reimburs uncertainti could overhang
time expect issu new propos rate howev recent indic approv two product code four code
vari payment rate code base wear durat time news extent allevi concern worst cast scenario
extended-wear monitor could reimburs rate tradit holter evalu sever potenti outcom subsequ impact
compani out-year revenu base compani current revenu share mix ultim believ concern around reimburs overdon
futur catalyst ahead form market-expand opportun mcot asymptomat silent af octob irhythm launch
mcot space broaden platform begin support top-lin growth compani invest develop
infrastructur necessari support extens mcot space last two year pilot launch order capabl provid near real-
time monitor expect irhythm gain traction introduc zioat servic exist share base abl break new account includ
larg integr deliveri network said think heighten acknowledg around import extend monitor gener ultim grow
first-lin extended-wear market well second-lin mcot market addit asymptomat opportun includ patient
 provid increment opportun support long-term growth
page
irhythm matter stock item compani sustain top-lin growth
strh thought ye think maintain next least
believ irhythm zio servic platform offer valu proposit extend across healthcar
system support robust portfolio clinic data demonstr efficaci econom benefit
compani clinic support view key driver top-lin compound-annual-growth-rate
clinic benefit zioxt platform demonstr thu far
long-term monitor benefit tradit short-term monitor standard care
analysi patient wear zio patch publish american journal cardiolog
august demonstr less arrhythmia occur first suggest
arrhythmia occur beyond therefor could miss
tradit holter monitor addit irhythm databas record identifi signific
incid rate first critic arrhythmia detect beyond demonstr value-add rel
tradit holter
improv diagnost yield patient prefer
undergo simultan ambulatori ecg record april juli
use zio tradit holter monitor zio demonstr improv diagnost yield
compar tradit therapi barret et al addit patient studi found zioxt
devic comfort wear compar holter monitor wear patient
prefer zioxt devic holter monitor
improv af detect lead improv clinic manag patient
single-cent studi patient undergo simultan ambulatori esg monitor use zioxt
holter monitor found zioxt identifi af event patient
compar tradit monitor zioxt find result chang diagnosi treatment
pattern af patient rosenberg et al march chang patient treatment
includ adjust antiarrhythm medic initi discontinu anticoagul
medic recommend pacemak placement atrioventricular junction ablat pvi isol
af burden predictor stroke risk
kp-rhythm studi retrospect studi kaiser permanent patient paroxysm af
monitor burden durat patient af per day risk ischem stroke
found af burden found associ increas stroke risk
us demonstr necess af burden collect zio servic may allow provid
better evalu option reduct stroke risk afflict patient
patient symptomat arrhythmia detect
day monitor
incid af diagnos critic arrhythmia
vt paus
incid first critic arrhythmia detect beyond
page
irhythm matter stock item compani sustain top-lin growth
strh thought ye think maintain next least
els lead strong growth thu far
behind irhythm compel valu proposit patient payor provid
manag commerci execut thu far driven top-lin
compound-annual-growth-rate think continu salesforc addit higher
averag product among exist newly-hir sale repres
support at-least top-lin growth next year assum reimburs
constant
last three year compani doubl size
sale forc expect end direct sale
irhythm revenu growth exceed growth sale forc headcount
sale repres expand new account also
abl go deeper exist account importantli third quarter
compani saw same-stor sale growth contribut sale mix
past averag annual sale rep full product grown
zio platform continu demonstr clinic valu
addit think combin product mix shift toward direct bill
contrast customer/provid bill payor increas
number contract payer predict payment rate
compar non-contract payer support grow averag annual
revenu per repres well improv oper leverag model
recent compani shift sale forc focu toward larger integr
deliveri network idn help compani scale addit
think recent full commerci launch zioat platform oct
nice layer compani product portfolio broaden
compani offer larger idn account seek first-
faster
total sale rep
averag annual sale per rep tenur
averag time new account reach zio rx/mo
page
irhythm matter stock item compani sustain top-lin growth
strh thought ye think maintain next least
us market penetr continu expand
us estim outpati ambulatori ecg diagnost test perform continu expand low-single-digit
compound-annual-growth-rate estim
estim current hold entir extend monitor market repres total ambulatori
ecg market
expect irtc market share continu expand alongsid grow market
page
extend holter extend holter market total market report growth report penetr ambulatori ecg market compani document strh compound-annual-growth-rate healthcar
irhythm matter stock item think reimburs chang impact stock
strh thought think bake
great effort irhythm zioxt servic wide cover payor live cover us even
without categori code place irhythm abl contract directli third parti payor self-pay program includ state
medicaid ensur payment place zio servic addit irhythm sale forc activ engag exist account review workflow
ensur physician effect util avail reimburs resourc
today irhythm gener revenu tie set negoti reimburs rate zioxt either bill provid client directli bill
client model today estim less rhythm revenu
irhythm sell zio servic directli hospit includ cost analysi curat zio report
hospit take reimburs risk thu zio servic sold hospit lower asp
direct model today estim make rhythm revenu
irhythm provid zio servic hospital/physician offic consign
provid bill payor applic zio devic analysi data/diagnosi zio curat report irhythm bill insur compani
directli zio devic data extract
direct bill model allevi provid reimburs risk also allow irhythm control bill process obtain higher
reimburs risk fall irhythm compani bill contract payor and/or uncontract payor zio servic
irhythm seen increas util account switch direct bill model expect trend continu
direct bill irhythm bill contract non-contract privat payer well directli
zio servic directli bill three separ code devic hook technic analysi servic interpret
code record includ connect initi hook
code technic compon scan analysi report zio proprietari algorithm major revenu
code interoper report physician zio report mail back physician
code older code encompass code roll one howev larg move away code
irhythm monitor center refer certifi independ diagnost test facil idtf includ independ medic offic site
bill directli analyz report code sinc analysi done irhythm idtf facil reimburs base
local medicar administr contractor rate facil locat compani three idtf us chicago houston
san francisco medicar volum direct houston sinc highest reimburs amount exist
code current reimburs novita
page
irhythm matter stock item think reimburs chang impact stock
strh thought think bake
reimburs rate hook-
 physician review
essenti
per unit direct
page
tradit holter global tradit holter hr scan analysi interpret cardiac monitor servic global extend cardiac monitor hr wk scan analysi interpret healthcar
irhythm matter stock item think reimburs chang impact stock
strh thought think bake
reimburs background next step
today rhythm bill temporari categori code howev american medic associ ama work sever lead
medic societi includ american colleg cardiolog heart rhythm societi hr establish perman code
follow ama editori panel meet end septemb hr propos replac exist temporari code
perman code approv octob ama plan expand exist four code set two new set four code
effect januari code differenti base wear durat though two new perman code set separ exist
holter monitor code mean like cover extend period beyond tradit holter wear-tim
januari irhythm collabor acc/hr ama rv updat committe ruc meet provid inform use
input payment model expect note meet made avail end februari cmss review approv
modif propos rate juli propos rate requir approv two-third ruc member final rate expect
establish novemb go effect januari
concern around signific reimburs chang weigh share irhythm given uncertainti associ payment rate
reimburs outcom simpli difficult fulli predict think next sever month first real news anticip end
februari reimburs overhang lift investor refocu fundament valu zio servic
page
irhythm matter stock item think reimburs chang impact stock
strh thought think bake
current standpoint issu play
physician fee schedul reimburs rule mandat cost-plu account approach transit temporari code perman
code howev could deviat cost-plu account product servic demonstr overal cost effect despit higher up-front cost
irhythm zioxt shown produc diagnost yield higher holter monitor believ support case
higher reimburs rel tradit holter product review profit margin market particip includ irhythm evalu
process provid support behind cost estim
note ama similarli transit mcot temporari code perman code establish payment rate mcot
transit perman code nation payment level medicar paid around mcot servic privat payer paid
medicar reimburs establish payment rate set set payment rate lower commerci payor follow
pay around medicar rate howev time mcot transit perman code mcot unit repres total
ambulatori ecg market limit clinic data support use therefor dont think reimburs transit mcot necessarili
great comparison extended-wear transit least believ bracket worst case scenario compani
assumpt use holter compar
overli simpl bear-cas analysi assum extended-wear payment rate directli walk upward base wear time use traditional-holt
rate scenario refer tradit holter current technic fee code reimburs use assum fix cost
includ rate walk variabl cost upward base wear time therefor extended-wear product wear would impli
technic fee howev think analysi overli conserv event decid distinguish reimburs
fix vs variabl cost believ reason bear case impli wear would assum allow full
monitor period extens think hook fee could award manufactur consider belief patient-appli patch
product like domin landscap long term potenti ad payment overal could bring reimburs
hook fee close current price analysi specul reason believ reimburs count actual
page
dayscurr extend cmconnection/disconnection/record scan analysi nation average review interpret estimate nation average healthcar
irhythm matter stock item think reimburs chang impact stock
strh thought think bake
model could impact arbitrari reimburs scenario
end estim direct bill portion total revenu repres come client bill model
assum medicar repres total direct bill revenu private-payor contract revenu repres direct
bill revenu privat payor non-contract revenu make direct bill revenu
sever addit assumpt signific impact model includ
final reimburs rate set
amount non-contract payor may adjust reimburs rate
percentag contract payor contract expir near-term
rate payor whose contract expir near-term would adjust reimburs rate follow new code
number contract directli tie rate today
non-contract payor near contract payment would affect time contract reimburs rate think contract
payment process take fulli enact
follow page attempt bracket potenti impact revenu base arbitrari reimburs scenario
page
irhythm matter stock item think reimburs chang impact stock
strh thought think bake
current irhythm model estim
revenu
revenu
revenu
revenu
scenario cut medicar reimburs
analysi assum unit growth rate estim would remain would adjust
contract payor would cut reimburs rate
contract payor lock contract beyond would chang reimburs
contract payor contract directli tie reimburs thu would cut reimburs lock-step medicar
scenario
non-contract payor reimburs would reduc scenario
bear case scenario revenu growth would still growth profil busi would remain
rang
given model verili contribut ou contribut contribut zioat go forward chang reimburs
diminish impact wherea point histor would greater impact overal top-lin revenu given
aforement impact top-lin
page
af/verili revenu growth revenu af/verili estim changescenario revenuescenario reimburs cut healthcar
irhythm matter stock item think reimburs chang impact stock
strh thought think bake
current irhythm model estim
revenu
revenu
revenu
revenu
scenario rais medicar reimburs
analysi assum unit growth rate would remain would adjust
contract payor would rais reimburs rate doubl medicar would scenario
contract payor lock contract beyond thu would chang reimburs
contract payor contract directli tie reimburs thu would rais reimburs lock-step medicar
scenario
non-contract payor reimburs would rais scenario
scenario estim follow chang outlook estim
risk analys
compani focus grow contract payor specif past intens focus sign
larg idn thu could underestim share contract payor would lock beyond window
page
af/verili growth revenu af/verili estimatesscenario reimburs increas changescenario revenu healthcar
irhythm matter stock what next beyond xt
think compani plenti runway continu drive adopt top-lin growth zioxt platform believ
compani launch real-tim monitor market mcot could repres valu driver compani time
addit believ compani potenti move asymptomat silent af opportun collabor verili
long-term market requir develop opportun estim includ patient unit state
full launch underway
third quarter irhythm began pilot launch real-tim mobil cardiac telemetri platform zioat servic announc
full launch octob
irhythm zioat offer provid real-tim connect zio platform irhythm monitor center allow physician
notif signific pre-determin arrhythm event
real-tim monitor capabl zioat roll-out requir addit invest infrastructur support platform
pilot launch platform fulli launch market octob
think market opportun repres compel adjac market compani provid full offer cardiac
monitor space new zioat account compani see revenu growth overal compani offer first-
second-lin option custom
mcot servic premium servic cost xt system higher revenu item portfolio
expect revenu per sale repres move higher
addit think push larger idn account support growth initi roll-out exist account given usag
larg concentr larger account
page
irhythm matter stock what next beyond xt
cardiac monitor hour data zio servic think compani long-term intent grow asymptomat
silent af market make strateg sens though intens market invest develop requir
said think compani done impress job bring zio servic platform market take share
market less foothold posit compani well capit opportun expect irhythm begin
develop market leverag healthcar util cost data come mstop studi expect present heart
rhythm societi hr meet may combin product develop verili studi
addit sever compani partner irhythm includ divers player field verili technology/data aetna payor
janssen pharma scripp translat scienc institut academ research pharma suggest market develop
associ risk concert effort share across healthcar spectrum think benefit earli af detect clear
stroke af patient shown prevent earli detect data present thu far mstop studi
promis though asymptomat opportun today remain call option model
background verili collabor equiti rais
earli septemb irhythm announc decis collabor verili alphabet compani develop health manag solut
american high risk af target risk asymptomat silent af partnership leverag irhythm arrhythmia
diagnost platform verili advanc health data analyt technolog
term deal irhythm paid verili up-front payment potenti anticip mileston payment
verili chose partner sever high qualiti leader vertic segment across healthcar continuum acceler collabor
project recent year includ miniatur cgm alcon smart len program verb surgic robot
addit compani indic invest verili partnership
view verili deal expand irhythm reach larger enrich cohort patient access verili health data analyt
technolog believ enabl compani easili identifi patient asymptomat patient popul
back-end two team focu collabor effort toward develop conduc form factor less intrus
wearabl watch effort grow patient wear time data collect think access patient data would better help
irhythm find patient well make easier payor identifi patient popul think enhanc form factor could
becom commerci avail back half think technolog market valid remain near-term develop
page
irhythm matter stock what next beyond xt
study-af single-cent single-arm prospect studi laid groundwork zio platform monitor use asymptomat patient zio
platform current indic use asymptomat patient think continu clinic effort area import drive broader adopt
specif believ long-term data mstop screen prevent stroke studi key demonstr clinic econom valu
bring coverag discuss payor influenc guidelin chang ultim drive adopt
mstop mhealth screen prevent stroke
publish journal american medic associ juli collabor janssen scientif affair studi util web-bas platform
remot recruit elig patient aetna commerci fulli insur medicar advantag program select women age men
age certain risk factor base potenti increas risk asymptomat af
full outcom data publish juli analysi data valid prior feasibl result demonstr study-af trial
patient activ monitor zio servic newli diagnos af compar observ control group receiv routin care
beyond increas rate diagnos af patient undergo immedi zio compar receiv delay monitor notabl
rel rate stroke myocardi infarct patient diagnos af show statist signific lower incid stroke vs
control myocardi infarct vs control patient diagnos af via prospect zio screen
addit activ monitor patient provid time data result physician intervent associ increas cost
single-cent single-arm prospect studi publish clinic cardiolog may turakhia et al enrol high risk previous undiagnos af
patient year age consid high risk two risk factor cad hf hypertens diabet sleep apnea histori
blood clot caus blockag vessel
studi patient af zio servic identifi patient sustain af atrial tachycardia previous gone
undiagnos addit patient within studi experienc af episod within first hour overlap tradit holter wear time
patient experienc longest episod outsid window highlight applic long-term monitor longer durat
af episod associ increas risk stroke
patient identifi af episod experi symptom thu suggest zio potenti valu asymptomat patient popul
trial similar mstop use devic studi asymptomat at-risk at-hom patient
result trial report februari intern stroke confer lo angel ca
list clinicaltri gov websit octob studi highlight healthcar provid payor interest identif diagnosi
monitor asymptomat af patient bristol-my squibb random patient identifi electron health record ehr
databas determin detect undiagnos af peopl year age older reduc stroke risk compar usual care use zioxt platform
page
presid ceo
kevin king serv presid ceo
irhythm sinc juli mr king held
sever leadership role three
decad experi healthcar
industri recent presid ceo
affymetrix publicli trade compani
field genet analysi
compani mr king held
healthcar hp medic
karim karti serv irhythm
sinc join compani juli
current role mr karti respons
research develop commerci
execut oper servic
mr karti signific experi us
global market healthcar
technolog servic industri prior irhythm
mr karti spent yea
recent presid ceo
matthew garrett serv cfo
irhythm sinc januari prior irhythm
mr garrett serv cfo navigen
inc provid genet test common
mr garrett held sever leadership role
career includ director busi
develop corventi inc vice presid
financ chief account offic
treasuri
financ director research develop
director strateg market price
affymetrix inc
evp product chief
judith lenan serv execut vice
presid product chief clinic offic
irhythm sinc juli ms lenan
also held execut role irhythm
includ execut vice presid
prior join irhythm ms lenan
serv vice presid busi
develop centura health major
integr healthcar deliveri system
state colorado
mark day serv execut vice
presid research develop
irhythm sinc may
compani sinc mr day held
variou leadership role research
develop system develop sinc
join compani
prior irhythm mr day work
develop investor
daniel wilson held role strategi
corpor develop investor
relat past month mr
wilson join inc
director head busi
develop prior held
multipl role morgan lastli
execut director healthcar
annual perform bonu determin
long-term incent award determin
vice-president educ train
region vice-president sale
current vice-president sale conventu orthopaed
vice-president hires/departur captur linkedin last month
compani file linkedin
page
compani report strh estim
page
initi hold pt
page
appli price-to-earnings multipl discount median med-tech larg cap peer group ep estim deriv
pt hold-rat share
organ growth strengthen across
segment busi
oper margin expand quickli
non-oper item lead higher-than-
robot capabl expand new area
drive higher expect revenu
unexpect slowdown core end market includ orthoped capit equip neg
impact weighted-averag market growth rate compani revenu growth
competit core end market either larg establish healthcar compani new
smaller competit entrant differenti technolog impact abil regain market share
multipl contract result new competit robot
higher expect dilut recent and/or potenti activ
inabl drive margin expans earn growth rel expect
integr risk recent and/or potenti activ
page
scenariobear casestrhbul roughli organ revenu growth mid-singl upper-singl digit earn growth multipl contract roughli organ revenu growth upper-singl digit earn growth multipl contract roughli organ revenu growth upper-singl low-double-digit earn growth multipl expans vs current healthcar
origin found recogn best class innov consolid
medic technolog space billion annual revenu compani grown
organ acquisit achiev leadership posit nearli market
compet offer diversifi portfolio product servic orthopaed medic
surgic neurotechnolog spine
busi stand today compani diversifi across three categori
orthopaed revenu includ complet portfolio hip knee implant
solut mako robotic-arm applic partial knee total knee total hip
comprehens portfolio trauma extrem product
medsurg revenu includ market-lead portfolio instrument solut
capit equip includ limit power em equip hospit bed electr
neurotechnolog spine revenu includ neurovascular product
solut less invas stroke therapi neuro power instrument includ limit
drill cut accessori ultrason aspir portfolio solut craniomaxillofaci
procedur full portfolio solut spine procedur includ implant biolog well
intervent product vertebr augment vertebroplasti radiofrequ ablat
compani file strh estim
buyback
commit
increas
dividend
ep growth
focus
growth core
adjac
compani file strh estim
page
stori remark consist high-qual earn growth outperform consensu earn estim almost
everi quarter last five year earlier year compani orthopaed exposur acquir contribut underli
growth though orthopaed busi medsurg busi sale slow began activ diversifi
revenu base bolt-on technolog case strengthen core busi other open new tangenti opportun
compani clear done great job execut short long-term goal maintain premium growth rate
go forward think compani valuat reflect perform addit think may bring concern around pend wright
medic deal new competit larg joint orthoped market potenti weak hospit capital-expenditure spend environ
think top-lin growth continu headlin risk consid consist deliv organ revenu growth
mid singl upper singl digit rang last five year expect abl deliv growth rang forese futur
expect growth driven increas exposur higher growth area medic technolog continu uptak mako robot
system said think headlin pressur sever competitor begin roll activ discuss larg joint
robot area may take time hospit evalu multipl system market addit think concern around potenti
weak hospit capit equip spend environ may increas make difficult compani substanti outperform market
wright deal make sens sale rep attrit may near-term issu clear think wright medic deal ultim
increas exposur sever highest growth area orthoped good long-term invest drive top-lin growth
howev transact expect close second half expect next sever quarter come level
sale rep attrit addit fact wright alreadi special sale forc place limit overlap two
compani upper extrem busi help overlap lower extrem trauma busi like take
time fulli integr two compani
expect earn perform weigh long-term outlook still good number lever pull
continu drive financi oper leverag busi though expect earn impact wright medic combin
may take time work dilut effect like long-term outlook think next month may bit choppi
page
 supplement organ growth
wright medic yet close
compani file strh research
page
matter stock item compani sustain above-market revenu growth
strh thought think ye multipl seem reflect
think sustain revenu growth high-end med-tech though believ compani current multipl reflect
expect mani growth driver last month continu drive growth come year across busi segment stryker
commit achiev categori leadership posit major market compet compani
priorit well organ invest research develop drive industri leadership key area decentr
oper model allow effici innov across organ
orthoped grow mid-singl high-singl digit rang organ growth driven strength knee
busi make total compani revenu tie increas interest mako robot system well growth
trauma extrem busi segment total compani revenu
knee busi own knee market estim offer complet portfolio implant solut
though major investor focu compani mako robot system estim global instal base nearli
system system alon target orthoped practic us think compani signific
runway grow orthoped busi next sever year import compani continu grow robot presenc
addit sever recent near-term entrant includ zimmer biomet globu medic next month though
believ space larg enough accommod multipl player
trauma extrem consist grown market rate major busi foot
ankl space compani grown busi organ sever tuck-in busi segment time includ
memomet small bone innov recent announc acquir wright medic focus extrem
biolog total enterpris valu billion orthoped deal tend come disloc integr process may
prove challeng two compani come togeth think scale design commerci team make clear leader
extrem space come year
page
matter stock item compani sustain above-market revenu growth
strh thought think ye multipl seem reflect
medsurg grow upper-singl low-doubl digit rang medsurg busi steadi workhors within
compani organ growth augment growth acquisit bolster medic busi
billion acquisit includ physio-intern diversifi segment away low-tech tradit capit
equip high-tech differenti capit solut dispos instrument endoscopi busi compani also
acquisit acquir novadaq bolt onto market-lead endoscopi busi compani acquir
invuiti instrument segment
neurotechnolog spine deliv mid-to-high singl digit organ growth last sever year larg driven contribut
neurotechnolog busi includ neurovascular product coil solut acut ischem stroke market
also acquir entellu help bolster nose throat ent busi includ neurotechnolog segment
spine busi hand challeng recent year though acquir strengthen
exposur high growth spinal deform segment theyv histor limit exposur minim invas procedur
differenti titanium solut view good strateg fit spine deal tend come disloc
integr process think combin help support above-market growth long-term
note compani revenu shift toward higher-growth busi segment last year shown
page
compani file strh estimatesbusi organ growthrevenu segment weight growth profilestryk healthcar
matter stock item integr wright medic
strh thought like wright deal long-term dilut potenti near-term disrupt give us paus
novemb announc acquir wright medic global medic devic compani focus extrem biolog total
equiti valu billion total enterpris valu billion includ convert note ev/sal basi close
transact subject receipt applic regulatori approv adopt certain resolut relat transact extraordinari
gener meet wright sharehold complet tender offer customari close condit
wright medic pure-play compani high-growth extrem biolog market expect gener total sale
full year mid point manag guidanc deliv consist constant currenc net sale growth double-digit rang go
forward market wright compet highest growth area orthoped grow year upper-singl digit rang
averag compani long-tim acquisit target smith nephew johnson johnson
name potenti buyer differ point time pure-play asset buy extrem space come growth
scale
strateg rational transact make sens grow stryker exposur upper lower extrem market add new
growth platform biolog augment digit technolog wright gross margin profil current sit rang
compani shown rapid improv adjust ebitda margin profil recent year
expect anti-trust review extend second half could see product divestitur lower extrem busi
deal expect close second half think could linger concern come quarter around sale
forc attrit wright special sale forc place today help mitig disrupt still expect
challeng combin two lower extrem sale forc product overlap certainli think best-equip
manag integr histor challeng extrem trauma spine combin even wright tornier integr
addit think clinic case cartiva wright synthet treatment arthrit toe convers early-adopt
physician suggest real-world result posit demonstr pivot trial like led materi slow-down
cartiva within wright portfolio realiz cartiva simpli one product portfolio mani though stryker comment suggest purchas
price place valu product
deal close late septemb expect transact impact adjust net earn per share
consensu current sit dilut vs consensu accret thereaft
page
matter stock item mako continu key growth driver
strh thought ye though new competit could make noisi
singl product garner attent portfolio mako robot system acquir mako surgic decemb
paid billion ev/ltm revenu multipl approxim time price-tag controversi mako
clear patient knee arthoplasti total hip arthroplasti though robot sinc expand addit indic includ total knee
clear launch limit releas roll broadli mako system allow surgeon better
plan execut surgic plan help protect soft tissu ligament damag ultim use market tool attract
surgeon patient facil full launch knee growth notic pick robot system help differenti
compani peer larg joint market today compani estim instal base global
expect sever addit player move larg joint robot market zimmer biomet show total knee system proto-typ
american academi orthoped surgeon aao annual meet receiv clearanc rosa knee system januari
compani limit launch rosa robot total knee expect broadli roll system
addit expect zimmer price system rang fairli wide rang well see launch
progress ultim think compani benefit implant pull-through surgeon begin grow util system
globu medic plan launch larg joint robot system end compani develop robot solut total joint
hip knee procedur last sever quarter expect launch system late second quarter globu also
announc acquisit stelkast manufactur total joint hip knee system long-stand histori produc suppli
product stelkast one origin supplier mako surgic
johnson johnson also acquir paris-bas orthotaxi orthoped surgeri robot prototyp expect orthotaxi robot
small footprint less expens robot system market system like debut think like
robot arm interconnect addit technolog offer depuy time compani linkedin depuy post
introduct veli digit surgeri platform connect technolog design autom procedur leverag data insight
improv orthoped outcom introductori video mention robot advanc visual instrument virtual realiti sensor artifici
intellig compon digit surgeri platform
total address hospitals/system potenti custom number custom may acquir multipl system
therefor think opportun larg enough sever player share said think could volatil capit
sell market hospit surgeon evalu new system
page
chairman ceo
group presid ortho spine
kevin lobo serv ceo sinc
octob mr lobo join
origin group presid orthopaed
held posit time
transit role ceo also
assum role chairman board
mr lobo held variou execut posit
gener manag financ career
prior mr lobo spent eight year
johnson johnson presid
medic canada presid ethicon endo
group presid medsurg
andi pierc serv group presid
medsurg neurotechnolog sinc
august compani
year mr pierc also overse sever
busi current capac includ
medic cmf sustain solut
healthcar system flex financi
mr pierc held sever leadership posit
long career recent
serv group presid medsurg
glenn boehnlein serv cfo
sinc april compani
sinc mr boehnlein held sever
leadership posit long career
transit role group
cfo medsurg neurotechnolog divis
held posit
time transit role cfo
cfo compani mr boehnlein
respons variou financ activ
treasuri intern audit
mr boehnlein strong track record
uphold financi standard practic
enabl growth prior mr
boehnlein spent three year success tv
vice-president strategi investor relat
katherin owen serv vice presid
strategi investor relat sinc join
februari ms owen
respons compani strateg plan
busi develop process well
investor relat
prior ms owen held variou
analyst posit merril lynch cowen
co /sg cowen state street bank
annual perform bonu determin
spencer stile serv group presid
orthopaed spine sinc august
compani sinc
mr stile also overse compani
joint replac trauma extrem
spine busi interim presid
mr stile sever leadership role
long career compani
includ presid spine presid
instrument recent group presid
neurotechnolog instrument spine mr
stile import contributor design
stryker transatlant oper model
also instrument sever key
presid
timothi scannel serv presid
sinc august
compani sinc mr scannel
respons stryker oper
busi region compani
mr scannel held sever leadership
posit recent group
presid spine endoscopi medsurg
neurotechnolog
total stryker perform threshold follow overachiev bonu potenti
perform exce threshold
group presid also compens base goal specif group
presid program melinda
gate foundat sinc prior current
role mr golston serv cfo cao
director bremer bank previous led
healthpartn presid ceo
dr datar held posit arthur low
dickinson professor graduat school
busi administr harvard sinc
serv numer board includ
novarti t-mobil
ceo chairman execut committe
ucb current
chairman glg healthcar institut
former vice-president raytheon former presid
missil system segment
chairman tucson medic center
healthcar board truste
former ceo inc prior
join avon ms mccoy spent nearli
year johnson johnson
chairman presid ceo
granddaught founder
presid ceo nokia sinc prior
current role mr suri serv ceo nokia
solut network
page
compani report strh estim
page
initi buy pt
page
appli multipl sale estim deriv pt in-lin median med-tech high growth forward top-
line growth peer group buy-rat share
competit core end market either larg establish healthcar compani new smaller competit entrant differenti
technolog impact abil regain market share lead price pressur
snm market continu develop expect due inabl chang physician mindset and/or influenc patient behavior
product launch includ next gener system delay and/or gain traction expect
commerci misstep compani grow sale forc clinic specialist team rapid pace
pend patent litig creat nois market requir increas spend ultim lead unfavor outcom
lack profit
page
scenariobear casestrhbul commerci take longer expect multipl compress assum lsd price declin us continu strength account addit well modest multipl compress ev/sal basi price stabl us continu strength account addit well multipl expansionupsid vs current healthcar
axon medic technolog compani headquart california origin incorpor american
restor medicin inc compani chang name axon around time
commenc oper sinc design develop test brought market proprietari
sacral neuromodul system r-snm use treat patient overact bladder oab
urinari retent ur fecal incontin fi devic commerci use intern
littl year receiv fda pma approv fi oab ur indic
page
 implant tripl usdaxnx revenu outlookus healthcar
pivot product launch green-light monopoli becom duopoli
decid snm
market financ
compani brought
agreement amf
ip relat
gener
compani file transcript
patient
approv
enrol
implant
kick
fda approv
fda approv
oab ur
bodi mri label
page
sacral neuromodul snm sometim refer sacral nerv stimul sn third-lin treatment option dictat reimburs
polici patient suffer overact bladder oab urinari retent ur fecal incontin fi found symptom relief
first- second-lin therapi
snm therapi design correct neurolog pathway control bladder bowel function stimul sacral nerv via low-voltag
painless electr current patient begin trial period involv implant temporari lead local anesthesia extern
stimul trial period last day week patient physician decid whether move forward perman implant
perman implant typic occur ambulatori surgic outpati set perman lead insert well insert
small incis pocket subcutan fat buttock trial patient typic return week initi trial period
devic stimul program adjust via small wireless remot thereaft urogynecologist urologist colorect surgeon
perform vast major snm implant
collater damag oab/fi
individu suffer symptom oab and/or fi often suffer silenc condit embarrass difficult bring
physician visit mani individu attempt manag condit independ one studi depart urolog surgeri vanderbilt
univers women oab symptom wait averag year symptom onset discuss symptom physician
symptom debilit impact qualiti life implic deterior physic social health loss sleep obes
inabl exercis avoid intimaci well econom impact declin work product indirect intang cost oab
estim publish american journal manag
patient profil oab
preval oab similar sex although women
like ultim seek treatment due manifest oab women
younger age symptom highli disrupt qualiti life typic
women oab commonli caus childbirth menopaus wherea
men oab commonli caus enlarg prostat affect roughli
men age age accord mayo clinic given
preval enlarg prostat sometim view normal part age
men may seek treatment
patient profil fi
accord popul adult within europ
candid snm therapi includ idiopath symptom
fi due obstetr surgic injuri trauma
page
sacral neuromodul deeper breakdown largest target market
address us snm market male femal age us estim roughli men women
address snm given preval oab gender preval patient within continuum care seek treatment applic snm
treat underli condit directli model snm readi patient popul male femal fail
line therapi undertr still seek relief femal idiopath wet oab leakag fail first line treatment repres
largest patient popul axnx snm technolog recent studi all-com oab diagnos suggest patient progress
line therapi indic under-penetr snm market opportun
page
first-lin therapi behavior lifestyl adjust conserv treatment option patient may advis drink
less fluid exercis perform bladder train exercis perform pelvic floor exercis schedul time void bladder
second therapi medic current treatment guidelin requir patient
tri fail two medic move third line therapi
anticholinerg commonli prescrib medic oab
mirabegron approv work reduc bladder
contract relax muscl bladder wall common side
effect observ clinic trial hypertens nasopharyng uti
oab
involv directli inject bladder
muscl botox
advers side effect includ uti
inabl void bladder requir
everi month maintain efficaci
patient discontinu
electr stimul tibial nerv
use extern neurostimul
treatment use address oab
advers side effect minim
requir thereaft maintain
non-surg
prescript yr mark
studi link lt use
anticholinerg dementia
minim invas surgeri involv
implant puls gener
stimul sacral nerv treatment
use address oab and/or fi
year axnx recharg system
approv year lifespan
requir biweekli charg
minut averag
page
axon emerg ambit bring disrupt product larg underserv market could differenti
highli desir product patient valu proposit healthcar industri manag team bring extens experi healthcar
demonstr track record execut compani check box cultiv axon evidenc rapid intern success
last year well go market success appear play far sinc compani fda approv
one devic market directli compet heavi weight public intent vehement defend
market howev think surgeon long desir innov market manag strateg plan pair tenur sale
forc believ axon success rapidli captur high singl low double-digit market share month launch addit
top-lin focu think compani hyper growth profil ultim translat strong profit come year
sacral neuromodul market alreadi larg despit low penetr expect pickup growth number driver
state snm busi gross global sale interstim ii offer full year estim snm market
seen steadi annual growth mid singl digit past year though overal penetr address market hover littl
estim age major common factor peopl suffer oab fi unit state snm implant take place
babi boomer current age largest gener cohort target market driven age global popul
innov offer welcom surgeon like increas recommend therapi patient compet third-lin
therapi deepen penetr expand market
axon well prepar enter space captur share axon undertaken rare approach build esteem salesforc
activ sought take rank emerg compani prior approv product manag state nearli two-third
compani sale forc today snm experi remain tenur adjac market addit axon fulli staf
salesforc sinc june translat minimum month train go market commenc top compani pinpoint
surgeon manag estim respons snm implant within rep tow shakeout
surgeon per trove that like contact met point time alway risk associ product launch
surgeon first mover watch adopt close forecast high singl low double-digit market penetr close one
hyper growth translat strong profit exist intern market estim axon taken market share
rather short time-frame think possibl share break mid-to-high-teen could translat
increment revenu need grow forc increas manufactur capabl time-frame feel
effort up-front market rais therapi awar gener roi well addit product innov drive upsid
page
pioneer sacral neuromodul space origin
interstim product back releas innov
version interstim ii sole offer snm treatment
oab fi ur
recent submit two pma submiss fda surescan
mri lead interstim ii devic new recharg devic call
interstim micro expect product approv spring
addit receiv fda approv new smart
programm decemb combin clinic programm
patient remot one touch screen samsung mobil devic
surescan lead surescan lead new product
new enhanc interstim system submiss
includ approv label feel like
approv given surescan lead approv
product welcom enhanc current mri
restrict neck major barrier implant
interstim micro compet directli axnx r-snm
smaller cc batteri expect r-snm
year file mri label vs held
r-snm vs could secur market share
particular patient sub popul like push
well especi receiv full bodi compat
label canada decemb
page
interstim ii axon r-snm systemimplant yearsexpect batteri yearsconst voltageamplitud controlconst currentclinician feet hold wireless feetblack/whiteappearanceful color lcdnoprogram recommendationsyesremot feet hold wireless systemn/afrequ minutestri systemyestin lead trialyesyesbilater pne trialyesn/a healthcar
axon matter stock item market enough
strh thought think plenti growth go around
sacral neuromodul proven treatment oab fi success grow sinc incept year ago given
tenur treatment option code well-establish cover insur current main code insert replac
devic reimburs per procedur current forecast asp per unit perhap room climb
base new innov market although conserv forecast slight asp declin given anticip competit
estim market stood annual sale end roughli patient estim
replac treat annual europ unit state unit state repres total implant howev think
market could doubl next five year
compil data multipl studi size market million peopl europ suffer oab and/or fi narrow
market million oab patient million fi patient candid snm therapi howev estim studi bit
date feel address market could trend slightli higher exampl stewart wf studi cite manag
determin estim oab preval date back base adult base million overal popul
 grown largest increas come older cohort fall within patient profil estim market potenti
doubl next five year model nearli expans
artisan-snm pivot studi began dec patient enrol implant june follow year uui center
 europ six month mark therapi respond studi met primari secondari efficaci
endpoint primari defin least reduct number urgenc leaks/day three-day bladder diari six-month post
implant still therapi respond one year mark check-in period implant patient report
satisfi therapi
relax-oab european studi commiss axon mid evalu patient suffer uui and/or uuf across seven site
patient subject trial implant therapi improv time percentag patient tick six month
mark oab respons rate test respond three-month mark vs month mark addit test
respond moder satisfi mark respond find charg durat accept
page
axon matter stock item market enough
strh thought think plenti growth go around
penetr
despit larg market prime benefit snm therapi penetr remain low target market receiv implant annual
number one reason cite patient adopt lack patient awar therapi like
product characterist contribut low adopt tradit physician hesit discuss snm treatment option
without discuss patient go unawar therapi compani implement strong market stimul discuss
even market success initi convers patient interest key driver surgeon interest implant
discuss surgeon think reason doctor stay silent stem seri handicap make current devic offer
interstim ii last resort vers go-to third line therapi one drawback product voltag control non-recharg batteri
requir patient undergo surgic replac everi year non-charg still go desir product select patient
feel freedom repeat surgeri attract mani second devic mri full bodi compat yet requir exclus surgic
remov patient requir mri neck lastli devic larger cc axon thought review factor drive hesit
snm devic use address product launch cover later
rise trend amongst patient demograph age obes diabet like experi oab fi expect annual implant continu
maintain recent msd upward trajectori least see acceler drive mid-teen growth view key driver
revenu acceler reserv held interstim ii size mri compat yr requir surgic replac
resolv innov offer come market see increas penetr expans market
bottom line expect market growth could acceler current rate driven demograph new demand given attract
therapi market fill pool larg enough one fish swim
page
axon matter stock item even larg market abl garner interest
strh thought surgeon appreci option especi theyr innov one
product patient want use snm address market larg yet sever under-penetrated care research
drawback interstim ii cite lack prescript design product remov hesit bar physician recommend
snm therapi product smaller size quarter full bodi mri compat user friendli control fda approv
year extend use could save patient undergo surgeri everi year studi commiss could result
save health care system next year
doctor told us theyr excit attend one axnx five physician train session late octob
opportun meet manag spoke sever physician attend physician train although
compani host five total train session collect includ physician regard experi current snm offer
heard lack innov space frustrat physician left littl tool help patient second concern voic
felt less satisfactori custom servic past cite ineffici commun cancel
gen interstim canada paus market interim ii emerg also observ complaint product tempera differ
trial perman implant experi devic longev program sum true physician year
relationship incumb number strong relationship satisfi patient dont feel physician
patient overwhelm current product innov servic receiv past two decad find secondari sourc
refresh sole relianc singl supplier
enter intern market great success opinion first began gener intern revenu back mid
growth explos view compani report hospit implant england denovo implant
quarter repres share estim annual procedur countri also rapid success
netherland estim share canada sole provid major hospit max annual quota
unit earli compar total unit implant
anticip fast roll-out state well less two week secur fda approv oab ur indic
announc formal agreement sandford health larg health system compris hospit state nine countri
alreadi begun implant r-snm expect mani announc like next month forecast rapid albeit
slower europ market share gain addit announc surgeon implant week pop
advertis penetr dozen state count see map next page
page
axon matter stock item even larg market abl garner interest
strh thought surgeon appreci option especi theyr innov one
experienc hungri salesforc recruit fee line tout manag time time abl attract
salesforc rep clinic specialist region manag two-third snm experi platform record
time team six month train product offer partner extern research firm abl
pinpoint physician current implant snm therapi unit state narrow list surgeon perform
snm implant annual shake account per rep feel confid initi convers like occur
weve collabor data scienc engin team track axon sale rep map locat high-volum physician
axon intend target abl pinpoint locat sale rep region manag find color
code map sale rep unsurprisingli densest state fl ca rep largest popul target demograph
lightest color repres one sale rep weve also monitor implant announc social media identifi
center across state perform implant within first month go market mark star chart rh
graphic axon target market
page
axon matter stock item bottom line show black
strh thought think could month
top high growth market product fli shelv grand sale translat profit think sweet spot
lie think possibl sale approach mark translat run rate unit per quarter think
ep free turn posit first time current optimist compani could hit mark first half albeit
requir addit headcount capital-expenditure support higher product still believ compani cash posit end
also model slight asp declin year competit pressur abil maintain rais price would offer addit upsid model
 expect stay roughli line recent quarter close taper
support two addit product launch long discuss would work develop backward compat origin
interstim ii lead thu enabl insert replac patient expir current devic also addit invest
place decreas recharg frequenc averag one per month vs current month offer better qualiti life expect
come market late second compani invest nonrecharg unit captur remain market inelig desir
inconveni recharg unit new offer expect come market time
sale market like largest fastest grow expens
compani sale employe without us revenu sale
compens base plu percentag revenu product sold
forecast closer compani also
invest advertis rais awar snm third-lin therapi
option market proven effect doctor begin
initi therapi discuss patient current case
expens may abl taper offer smaller appreci none
less lift bottom line
page
million usd free posit healthcar
presid ceo
april
august
mr cohen ceo axon bring
year medic devic experi also serv
board
develop market hematolog oncolog
axon second publicli trade medic devic
compani mr cohen ceo
cardiac scienc also ceo vessix vascular
acquir
previous serv bod zurich-bas
lifewatch maker ambulatori electrocardiogram
servic acq jul chairman
bod lombard medic chairman bod
mr dearen serv presid sinc cfo
sinc prior serv presid mr dearen
chief oper offic
mr dearen long histori work life scienc
field partnership ceo raymond cohen
time vessix vascular held role
chief oper financi offic
respons integr prior
mr dearen cfo number life scienc
ventur capit firm includ mirav hold
medic deliveri devic posit ventana
januari septemb dr noblett
serv physician advisor assum role
chief medic offic octob
time serv physician advis also
professor depart chair ob/gyn
univers california riversid
prior experi univers california
riversid relationship dr noblett
serv professor divis director
univers california irvin dr noblett complet
univers california irvin
resid obstetr gynecolog univers
california irvin fellowship femal pelvic
medicin reconstruct surgeri
august
octob
mr sama took dearen august
prior role mr sama compani
sinc may serv vice presid
oper qualiti control
prior join mr sama serv director
oper qualiti vessix mr sama hold
biomed engin univers
dr jiang join assum role
octob prior join dr jiang spent
year director research develop director
engin engin manag amf
earn ph biomed engin
univers southern california lo angel
john woock current hold chief market
offic role within held role
global market clinic oper vice-president
product market vice-president sinc join june
prior join postdoctor fellow
sanford biodesign program stanford univers
prior spent three year engag
manag mckinsey co also experi
research fellow kentucki spinal cord injuri
research center mr woock earn ph
biomed engin duke univers
current establish
bonu plan polici execut director
bonus approv compens
committe time time base
march chair compens
committe sinc juli mr wisniewski
andrea partner sinc
sinc mr ambl serv chair
neom manag manag neom
innov vc focus support
entrepreneur young busi hc
michael carrel serv bod sinc feb
presid ceo
nanci snyderman serv bod sinc
april dr synderman board-certifi
head neck surgeon experi
board healthymagin
juliet bakker serv bod sinc
ms bakker serv manag director vc
robert mcnamara member bod sinc
mr mcnamara extens histori
work medic devic commun
jane kiernan serv bod sinc april
mr keirman year
leadership experi hc
page
compani report strh estim
page
initi buy pt
page
appli price-to-earnings multipl discount median med-tech larg cap peer group ep estim deriv
pt buy-rat share
unexpect slowdown core end market includ cardio spine neuro surgic neg impact weighted-
averag market growth rate compani revenu growth
competit core end market either larg establish healthcar compani new smaller competit
entrant differenti technolog impact abil regain market share price pressur
product launch includ hugo robot system delay gain traction market
inabl execut target top-lin margin expans goal
page
scenariobear casestrhbul bp lower earn growth vs base case multipl contract current levelsassum msd revenu growth acceler current level earn growth compound-annual-growth-rate hsd multipl expand current level assum bp higher earn growth vs base case multipl expand current levelsupsid vs current healthcar
industri leader medic devic space pioneer innov numer
market sinc found broad portfolio product divid four busi segment
cardiac vascular group cvg includ implant af ablat valv stent graft
gastrointestin endoscopi product airway ventil product renal patient monitor
restor therapi group rtg includ wide varieti product use brain
neurovascular brain modul neurosurgeri product specialti ent pelvic
health product pain spinal cord stimul implant drug infus nerv
ablat well spine biolog spacer implant fixat system graft
diabet includ insulin pump continu glucos monitor
fy sale segment
littl less half
medtron revenu
gener outsid
unit state
presenc approxim
page
expand
becom
devic compani
expand
world
found
develop first
spinal
invest
launch
pacemak
page
icon compani medic devic space robust histori pioneer healthcar technolog decad earli
compani combin covidien emerg world largest medic technolog servic solut provid gener
billion annual revenu scale abl partner hospit custom offer uniqu solut servic differenti
compani small mid-siz compani domin player across busi segment though point along way
unfortun common matur corpor think compani simpli grew comfort market posit howev siren
sound competitor small larg emerg new differenti technolog appear woken
rapidli reinvigor current portfolio offer pursu attract high growth market robot innov
re-establish forefront med tech innov
unpreced pipelin offer consist steadi flow new product year latest pipelin includ
sever transform launch led particularli impress roll-out new product continu flow
feel trend flagship past merg present compani reinvigor leadership posit etch
compani histori separ robot pipelin includ product launch new next-gener across platform hit larg
high growth market tavr diabet robot
robot oper room excel medic technolog field decad success multi-prong
strategi organ innov forefront present attract opportun demonstr mastership
integr expect area expertis visibl compani establish robot space purchas
mazor robot system use spine surgeri market made substanti invest hold consider share
acquir expertis pair proven track record navig enabl technolog imag posit success
launch next robot system hugo hugo target soft tissu surgeri field current own intuit surgic rare one
product move needl compani like simpli given size revenu base though hugo potenti
reason believ launch key focu investor kick initi launch
top-lin growth drive flow manag know weve review manag incent strateg goal
drive top-lin growth see long-rang goal sale growth compound-annual-growth-rate achiev driven momentum new product
cycl fulli expect invest continu organ inorgan front expand beyond near-term horizon inorgan deal like
limit tuck-in deal rather transform acquisit expect top-lin growth flow model drive consider free
cash flow gener expect compani exceed commit return sharehold
page
matter stock item gain traction broadli robot
strh thought theyv got experi relationship innov success penetr
want robot oper room robot work conjunct surgeon oper room design intent
improv outcom beyond physic human alon could offer case miniatur effector attach robot arm
go human hand perform minim invas procedur proven reduc risk patient faster recoveri time
import patient hospit current robot market perform wide array surgic applic includ
ortho spine gener surgeri gynecolog urolog sever
arent robot expens ye cost one major barrier broader adopt time regard up-front capit
invest well cost per procedur current intuit surgic main player robot soft tissu surgeri three variat da
vinci robot da vinci da vinci xi da vinci sp market capit unit cost rang second major cost
compon cost per procedur current significantli higher establish minim invas procedur believ increas
competit new player enter market well help hospitals/surgeon overcom barrier drive low util current instal base
execut less surgeri per day soft tissu robot increas surgeon train could help lower cost lastli invest
robot help establish hospit reput surgic area turn help attract patient surgic talent center fuel
wrap decad compound-annual-growth-rate
page
matter stock item gain traction broadli robot
strh thought theyv got experi relationship innov success penetr
current experi robot
medtron first foray robot though partnership mazor compani
pioneer first robot system spine surgeri
first invest mazor partnership develop maxor
legaci gener mazor renaiss approv spinal surgeri sinc
partnership launch mazor gone well rel histor launch
robot underscor support robot spine healthcar commun
acknowledg mazor renaiss intutit surgic da vinci first
market thu prove action speak mazor launch took
month place unit less half time intuit roughli fourth
time mazor renaiss
launch mazor proven abil innov around system
integr expertis navig imag mazor stealth launch unit
state januari two month fda approv system pair tradit
mazor medtron stealthstat navig ad degre freedom
depth screw real-tim reconcili rel surgic plan two unit
compat o-arm imag system provid visibl surgic
feedback within investor event septemb medtron
announc accumul mazor stealth case thu far across
 hospit total placement unit mazor launch
late mazor stealth rise instal base inclus
focus surgic synergi strategi offer fully-integr procedur
solut spine implant navig intra-op imag surgic plan
execut confirm pay seen recent rtg growth think
extend lesson learn surgic synergi strategi gener
surgeri market launch hugo
page
matter stock item gain traction broadli robot
strh thought theyv got experi relationship innov success penetr
soft tissu market procedur basi even bigger robot offer similar benefit soft tissu space spine includ
fewer complic shorter hospit stay overal faster recoveri translat less cost system
current surgeon train exist instal base soft tissu robot around world util remain low less
procedur per day across unit place global basi estim robot assist surgeri market arena
million plu surgeri year grow mid-to-upp teen open surgeri provid greatest risk longest
recoveri patient still repres global procedur
market today million surgeri annual accord manag
procedur
procedur
procedur
page
matter stock item gain traction broadli robot
strh thought theyv got experi relationship innov success penetr
hugo septemb unveil first soft-tissu robotic-assist surgeri ra program dub hugo hugo
modular platform design allow mobil oper room surgic arm individu unit allow greater util within
hospit surgeri requir four arm allow machin roll oper room increas optim surgic tower
univers tower allow use laparoscop robot case tower sold medtron gener capabl
power devic robot laparoscop open surgeri visual system power storz also use mode
common laparoscop procedur one featur highlight upgrad product hospit
area consider develop process
import hugo expect ra major driver growth within mitg capit equip sale well pull-
surgic input stapl hugo compet davinci system two decad success
market weve observ strong reput qualiti skill machin nonetheless except histori
come technolog strong long-stand relationship medic commun capabl balanc sheet ensur success ra
current train surgeon surgic product annual estim surgeon around world alreadi
train ra
strong foothold within medic commun high usag
respect surgic instrument gener surgeri think integr
medtron exist surgic tool robot allow surgeon continu use
product familiar like stock shelv today reduc one
potenti barrier introduct also think medtron stand relationship
valu access committe experi capit sale help grow
timelin placement ou addit clinic data gather follow expect
begin back half calendar goal ce mark submiss
calendar file calendar current
increment top-line growth mitg outlin call less basi
point bp bp street current
estim mid-singl digit overal revenu growth next sever year ra
contribut could meaning
follow similar slightli acceler cadenc intuit earli day
averag sale price per unit could see lift mitg segment
base unit shipment alon
hugo first introduc sept
page
matter stock item robot cool els got
strh thought robust pipelin across portfolio
depart ceo omar describ current pipelin strongest compani histori beyond ra platform mitg
launch launch multipl import product year fiscal impress pipelin ahead across
remaind portfolio cvg rtg diabet
page
matter stock item robot cool els got
strh thought robust pipelin across portfolio
line-up cardiac vascular group
evolut-pro tavr tavr transcathet aortic valv replac fast grow market import one sale
leap overal back fda august decis allow expans low risk market evolut-
pro launch second quarter fiscal earli driven acceler number procedur implant
linq reveal linq wireless implant cardiac monitor record subcutan electrocardiogram patient requir long-term
monitor and/or on-going manag version first waferscale-bas devic insert loop monitor area offer five
year batteri two year beyond current gener bluetooth connect addit sensor
micra av micra av leadless catheter-impl pacemak expand current micra tp offer patient atrioventricular
block normal sinu rhythm data support studi marvel publish journal american colleg cardiolog
novemb subsequ submiss micra av approv fda current micra unit share singl chamber pacemak
market accord product could meaning new indic expand micra particip
bradycardia market expect micra av becom avail
launch drive current growth
micra vr
size
page
matter stock item robot cool els got
strh thought robust pipelin across portfolio
pipelin diabet
diabet high-growth segment constant currenc fairli small portion overal revenu
revenu fiscal
minim drove growth fiscal though pressur competit offer build-up anticip
upcom launch howev drive strong growth intern launch demonstr demand
ahead minim roll pathway allow patient either warranti new therapi
purchas minim switch upon avail addit charg minim hybrid close loop system bluetooth
design take step autom correct bolus base sensor read goal increas time-in-rang
current minim system averag time auto mode near vs trial enrol product began june
includ adult pediatr patient pivot data expect present attd confer februari approv slate
guardian sensor non-adjunct juli file pma approv fda non-adjunct label guardian sensor
expect approv sometim earli mid winter label could open medicar market current requir non-adjunct product
leadership invest
given high growth seen diabet taken appropri step
solidifi posit market leader segment octob sean salmon
assum leadership divis come posit svp coronari
structur heart divis within cvg addit announc mid-decemb
acquisit behavior-track softwar compani name klue
technolog intend incorpor person close loop pcl insulin
pump system system current develop receiv breakthrough
devic design back februari expect launch sometim next
month time-in-rang improv upon launch goal
klue acquisit one layer dedic space novemb
also acquir isra nutrit data start-up nutrino health
also partner nonprofit tidepool develop interoper autom
page
matter stock item robot cool els got
strh thought robust pipelin across portfolio
pipelin restor therapi group
weve alreadi discuss implic mazor spine brain therapi divis within rtg addit
pipelin offer pelvic specialti therapi
sacral neuromodul snm enhanc interstim micro interstim ii surescan lead
estim gener snm sale interstim ii surescan lead enhanc legaci offer
addit full bodi mri compat interstim micro intend first recharg offer significantli smaller
size vs interstim ii axon r-snm therapi feel degre interstim micro concept come
respons competitor entranc think expans offer across patient profil well leverag current portfolio advanc
technolog product enhanc use surescan lead welcom patient doctor alik market
forecast doubl next five year
addit product launch within rtg includ next-gener intraop nerv monitor system nim vital percept pc deep brain stimul
incorpor new technolog allow record brain signal data implant lead offer patient tailor therapi catalyst includ
unveil next-gener nan
line commun open recent begun regular call seri investor leadership within product divis offer
deeper vantag point reinvigor effort product pipelin appreci commun add confid
taken necessari step candidli review market posit humbl accept shortcom tact strateg execut instat
bottom line listen research market end posit refresh innov pipelin
strateg plan commun investor-focus manag team chang tune like sound
page
matter stock item alloc cash flow
strh thought fuel growth innov tuck-in maxim sharehold valu
fire cylind front-end capit alloc strategi steal limelight
manag annual incent plan tie directli tie valu creation annual incent plan includ equal weight target mirror
initi guidanc revenu growth non-gaap dilut ep exceed beat initi guidanc across board
sale vs guid ep vs guid convers vs guid far anoth stori
beat rais except diabet slightli softer expect
long-term perform ltpp measur target achiev
well align view summar tabl right think three goal
attain forecast top-line growth
forecast believ compani continu
deploy share repurchas dividend maintain target dividend
pay-out ratio minimum return sharehold
ultim innov experienc well align manag
team rate buy pt
return sharehold past
continu grow dividend base
div
share repurcha
page
omar ishrak serv ceo chairman
board sinc june mr ishrak retir
ceo april announc
august mr ishrak becom execut
chairman follow retir continu
chairman board
mr ishrak focus three core strategi sinc
join compani includ therapi innov
econom valu global mr ishrak
engin acquisit covidien billion global
manufactur surgic product suppli prior
mr ishrak spent year ge
held sever leadership role recent presid
ceo ge healthcar system
evp presid cardiac
vascular group
michael coyl serv execut vice presid
presid medtron cardiac vascular group
sinc join compani decemb mr coyl
overse four busi divis
respons provid strateg direct ensur
align integr growth plan cross-funct
prior join mr coyl provid leadership
consult servic privat equiti ventur capit
geoffrey martha appoint presid
novemb assum role
ceo follow mr ishrak retir april
prior role mr martha held sever leadership
role recent execut vice
presid presid restor
therapi group rtg respons
therapi specialti therapi spine
mr martha led acquisit covidien
name chief integr offic juli
lead integr covidien prior
mr martha spent year ge
held sever execut role recent
manag director busi develop ge
evp presid minim
bob white serv execut vice presid
presid minim invas group sinc
decemb prior role mr white serv
senior vice presid presid medtron asia
pacif becam fastest grow region within
mr white led integr
covidien across australia new
south korea
prior mr white held sever leadership
posit covidien
annual perform bonu determin
annual incent plan includ equal weight target
mirror initi guidanc revenu growth non-gaap
dilut ep
vice-president hires/departur captur linkedin last month linkedin last month
evp cfo
karen parkhil serv execut vice presid
cfo sinc join compani june
current role ms parkhil lead
medtron global financ organ respons
key support function includ treasuri
busi develop corpor strategi
prior ms parkhil serv vice
chairman cfo five year
evp presid
brett wall appoint execut vice presid
presid restor therapi
group rtg novemb current role mr
wall respons
strateg direct oper manag rtg
specialti therapi spine
prior acquisit covidien mr wall
serv presid neurovascular
covidien manag commerci activ
function busi result doubl revenu
tenur
evp presid diabet
sean salmon appoint execut vice presid
presid medtron diabet group octob
compani sinc
current role mr salmon respons overal
strateg direct busi prior role mr
salmon held sever leadership role
recent presid coronari structur heart
within cardiac vascular group
mr salmon close year experi
medic devic pharmaceut industri held
previou role cr bard johnson johnson
surgivis eurorscg life
vice-president educ train
region vice-president sale
current vice-president sale conventu
page
compani report strh estim
page
deep dive spine anatomi procedur review
page
deep dive spine anatomi procedur review
anatomi spine
spine key structur support system bodi
design provid balanc stabil also protect
spinal cord nerv intern organ
structur made vertebra segment
cervic flexibl part spine upper segment
neck
thorac middl segment spine made
lumbar load-bear segment spine reach
top abdomen way pelvi
commonli refer one structur
commonli refer one structur
normal spine slight curv inward top bottom
structur refer lordosi middl segment
spine curv slightli outward curvatur call kyphosi
nation institut arthriti musculoskelet skin diseas
page
deep dive spine anatomi procedur review
issu spine
osteoporosi diseas bone character low amount calcium weaken bone lead fractur
sudden back pain fractur refer vertebr compress fractur vcf gener treat vertebroplasti
surgeon insert needl diseas vertebra inject bone cement fractur kyphoplasti
surgeon dilat balloon insid bone order expand vertebr bodi fill vertebra bone cement
degen disc diseas common mechan issu spine respons chronic back pain
defin deterior one spinal disc sit vertebra spine
issu spine relat
spondylolisthesi vertebra slip forward onto vertebra
spinal stenosi disc migrat caus canal contain spinal cord narrow
deform abnorm degener structur spine
treat
lifestyl chang medic manag patient present treatment paradigm gener begin
lifestyl chang weight loss anti-inflammatori pain medic howev gener medic manag allevi
pain temporarili fix revers diseas therefor major patient ultim requir surgic
discectomi patient present structur stabl spine surgeon may choos perform discectomi discectomi
fairli common unit state procedur surgeon remov part spinal disc
spinal fusion patient present spine deterior significantli either degener deform tumor
traumat episod surgeon may perform spinal fusion fixat procedur common type fusion procedur call
interbodi fusion interbodi fusion diseas disc remov replac spacer spacer typic fill
biolog biolog help activ stimul bone growth fusion surround vertebra fuse one bone
pedicl screw rod fasten spine help support structur bone fuse sever month
page
deep dive spine anatomi procedur review
type fusion
interbodi fusion cervic spine
surgeon choos perform cervic interbodi fusion he/sh typic
make incis front anterior patient neck
remov diseas disc
replac diseas disc plastic spacer metal cage fill biolog
screw metal plate adjac vertebra stabil fusion use
low/zero profil spacer requir hardwar
estim littl less cervic interbodi fusion unit state
year
histor cervic interbodi fusion okay great solut patient
given limit motion post-fus motion especi import cervic
spine reason motion preserv disc mpd becom popular
mpd gener insert vertebra simpli replac diseas disc
remov product requir fixat rod screw gener
spike keel clench onto bone product design
featur nativ disc theyr one spine product approv
pma pre-market approv pathway therefor typic fairli comprehens
data set come market
estim around cervic motion preserv disc case year
page
deep dive spine anatomi procedur review
type fusion
interbodi fusion lumbar spine
estim approxim lumbar interbodi fusion year unit
state surgeon choos perform lumbar interbodi fusion he/sh sever
one choic perform tradit posterior lumbar interbodi fusion plif
he/sh typic
start incis midlin back
dissect muscl ligament expos spinou process lamina
use retractor push muscl tissu asid remov boni debri
surgeon see nerv spinal cord
move asid dural sac expos diseas disc
remov diseas disc
fixat bone drill screw vertebra lock metal rod
insert plastic spacer metal cage vertebra
transforamin lumbar interbodi fusion tlif surgeon would use similar
approach plif except he/sh would perform procedur one side patient
spine approach disc diagon rather vertic back patient
page
deep dive spine anatomi procedur review
type fusion
interbodi fusion lumbar spine cont
altern approach anterior lumbar interbodi fusion alif procedur surgeon
start incis front patient
move asid blood vessel expos spine
remov diseas disc
place plastic spacer metal cage biolog two vertebra
fixat secur anterior plate stabil spine
alif case gener requir rods/screw though patient must stabil spine
also done plif fusion spacer implant anterior
screw rod place posterior
anoth option surgeon may choos perform later lumbar interbodi fusion trans-psoa
surgeon typic
start patient posit his/her side
make two small incis one waist one slightli posterior initi cut
cut fascia move psoa muscl insert probe detect avoid nerv
area
insert dilat tube probe creat larger open follow retractor push
back muscl tissu better visual
insert spacer biolog vertebra
later procedur typic requir much less tissu muscl cut improv recoveri
page
deep dive spine anatomi procedur review
mention normal spine includ slight curv inward top bottom structur commonli
refer lordosi contrast middl segment spine curv outward curvatur
spine curv pronounc hyper-kyphosi lordosi straight
hypokyphosi refer spinal deform spinal deform result pain and/or lack
common spinal deform call scoliosi scoliosi sideway curvatur spine
three type scoliosi
congenit rare discov birth shortli
idiopath common present adolesc reason unknown
adult occur result age
non-invas therapi start condit sever surgeon typic wait patient
adolesc stop grow allow full format spine oper
spinal fusion surgeon correct curvatur spine use fusion techniqu
typic much complex procedur gener high asp case
scoliosi
page
deep dive supplement market background
page
deep dive supplement market background
larg under-penetrated chronic pain expans opportun
million individu unit state estim lower back pain lbp accord nation institut nih
individu suffer lbp longer qualifi pain chronic
treatment lower back pain includ behavior physic modif pharmacolog approach surgic intervent
depend level diseas sever
patient mechan issu spine includ degen disc diseas surgeon may perform spinal fusion
weld two vertebra togeth one singl solid bone elimin pain motion mention estim
spinal fusion unit state annual basi split equal thoracolumbar cervic
spinal fusion fairli common outcom remain sub-par low success rate primari spinal surgeri moreov
repeat spinal surgeri success rate diminish time
accord public asian spine journal april patient undergo spinal surgeri
continu experi pain condit refer fail back surgeri syndrom fbss surgic end stage
one multipl surgic intervent lumbar spine without effect surgic intervent would frivol
patient experi chronic lower back pain may also experi chronic leg pain given pain signal travel lower limb along
spinal column lower back
complex region pain syndrom crp chronic neurolog condit character sever pain limb arm leg
often caus surgeri trauma minor injuri vari sever result signific impair daili live
qualiti life qol individu crp experi two type pain
crp type pain occur absenc identifi nerv injuri limit singl peripher
nerv crp
crp type ii burn pain occur region limb distinct partial nerv injuri
lower back pain leg pain treat similarli patient progress along continuum care pain persist
earlier stage intervent techniqu includ steroid inject nerv block
advanc therapi includ spine surgeri fusion treatment oral opioid and/or spinal cord stimul
spine surgeri common howev outcom remain sub-par result complic fail back surgeri
syndrom fbss pain still persist procedur
oral opioid caus multipl complic highli addict easili abus
page
deep dive supplement market background
page
deep dive supplement market background
type neuromodul therapi use manag chronic pain caus remov injuri repair
procedur puls gener implant lower back/upp buttock area attach lead tunnel
skin deliv electr puls spinal cord electr puls mask interrupt pain signal transmit lower
back and/or peripher nerv limb brain depend modal deliveri pain signal either perceiv
brain replac tingl pin needl feel refer paresthesia
tradit paresthesia-bas deliveri movement patient caus unpleas sensat caus lead movement
well potenti shock jolt sensat patient given patient may restrict daili live activ
advis drive oper machineri treatment deliveri well advis avoid stretch twist motion time
technolog evolv innov space led paresthesia-fre sub-percept base deliveri aim limit
discomfort associ feel paresthesia
clinic outcom technolog vari base overal neural dose defin product frequenc puls width
amplitud player space differenti technolog base proprietari optim frequenc puls width amplitud
prior innov therapi advanc space larg center around optim deliveri
precis therapi improv outcom rather elimin feel paresthesia altogeth
address market
common use technolog patient suffer neuropath pain result fbss crp repres
second common use technolog addit technolog use mitig peripher neuropath pain caus nerv
damag beyond spine well pain caus ischemia
beyond advanc electr deliveri paresthesia-free/sub-percept innov lead design increas durabl reduc
occurr lead migrat fractur reduc invas procedur support expans overal
histor focus predominantli chronic leg pain manag given efficaci leg vs back pain said superior
nvro data senza-rct studi technolog first paresthesia-fre technolog support use
technolog patient lower back pain thu see expand market technolog
first fda approv spinal cord stimul devic develop continu year market grown
ww market estim
page
deep dive supplement market background
current indic implant use aid manag chronic pain trunk limb patient
fail convent medic manag despit indic nation coverag determin ncd subsequ
reimburs polici electr nerv stimul qualifi use devic treatment pain late last resort option
treatment modal pharmacolog surgic psycholog physic fail
within fbss space demonstr clinic efficaci predominantli relief radiat leg pain rather primari back
north et al rct studi complet use patient experienc radicular pain without lower back pain
success defin reduct pain satisfact treatment patient compar
patient underw reoper
retrospect analysi patient fbss demonstr experienc less half
complic compar underw reoper vs
therapi implant trial requir ahead perman implant therefor typic act lead indic growth order
receiv perman implant patient must pain relief least trial period long
spinal cord stimul procedur perform pain specialist anesthesiologist neurosurgeon
implant paresthesia-bas technolog requir physician perform paresthesia map order properli place
lead along spinal column best coverag thu requir patient awak repeatedli question order
physician understand placement deliv optim efficaci
elimin sourc pain rather mask interfer pain signal pathway brain
spinal cord stim goal reduc pain given subject natur pain sever qualiti life impair
caus lower back and/or leg pain reduct pain even small amount signific daili life qol
refer advanc therapi surgic spine fusion typic indic ahead implant given goal
elimin pain point oppos mask interrupt pain signal thu given growth spinal fusion sub-par success rate
see larg under-penetrated market opportun patient
technolog advanc extend batteri live recharg system last year paresthesia-fre
sub-percept technolog avail intend improv patient experi
go forward advanc sub-percept base deliveri method think emerg sham-control
could gener robust clinic data support expans addit indic given rel subject natur head-to-
head trial
page
deep dive supplement market background
player space
launch follow data present nan spectra wavewrit system focus option
waveform deliveri offer patient combin sub-percept paresthesia-bas frequenc
bsx whisper random control trial rct random receiv sub-percept supra-percept
paresthesia-bas stimul cross receiv altern therapi subject trial
previous implant devic averag year studi met primari endpoint demonstr non-
inferior supra- sub-percept stimul sub-percept patient supra-percept
patient experienc reduct va score impli increas respond rate patient could
chose effect option compar supra-percept alon patient studi prefer sub-percept
compani present rct data nan use wavewrit system combin modal compar
tradit combo study- combin mechan better outcom
compani plan softwar updat launch wavewrit platform
launch intelli evolv workflow system adaptivestim technolog offer option
subthreshold high densiti hd densiti ld therapi automat adjust amplitud puls width electrod
configur maintain optim therapi
incorpor snapshot real world data captur record chang function provid data enhanc clinic decision-mak
evolv workflow standard guidanc physician trial perman implant period
mdt hd retrospect analysi analyz hd-program patient patient experienc
reduct va score
launch proclaim xr system octob burst micro-dos stimul patient creat sustain pain
relief less batteri usag abt burst altern low frequenc waveform offer individu pain relief use therapi
hour less per day reduc need constant batteri recharg enabl recharge-fre system
abt sunburst studi random receiv one stimul mode tonic burst first
simul follow patient experienc reduct va score week
patient prefer burst stimul tonic stimul sustain
page
deep dive supplement market background
player space continu
nevro launch senza omnia platform novemb incorpor option tradit tonic pair nvro
technolog build compani senza-rct clinic trial demonstr superior treatment leg back pain
compar tradit tonic patient experienc primari back pain patient experienc primari
leg pain achiev reduct va score compar control tonic arm
averag recharg time
freedom platform util puls electr current extern worn wireless antenna implant stimul side
current deliv pain relief smaller elimin need subcutan tunnel placement intern batteri
procedur complet outpati procedur standard needl avoid need gener anesthesia larg surgic
extern wearabl antenna requir daili charg last singl charg
evok ecap-control evok compound action potenti closed-loop spinal cord stimul system measur spinal cord
respons stimul adjust puls deliv optim activ within patient therapeut window
us compani current investig double-blind random control us pivot studi earli result
present intern neuromodul societi june
evok us pivot trial patient receiv closed-loop stimul experienc reduct
va score compar control group closed-loop activ maintain spinal cord activ within
therapeut window control group time closed-loop vs time control closed-
loop system met pre-specifi endpoint
avalon australian studi patient experienc pain relief reduc elimin opioid
medic patient patient experienc clinic meaning improv qualiti life qol
avalon studi conduct prospect single-arm studi
receiv ce mark approv septemb
june compani close term loan equiti round includ invest
compani recent close seri led glaxosmithklin ventur capit fund back
page
deep dive cardiac monitor supplement market background
page
deep dive cardiac monitor market background
ambulatori ecg devic market product growth categori
continu monitor period combin wire-fre patch-bas wearabl biosensor proprietari cloud-bas analyt platform
help physician monitor patient diagnos arrhythmia
wearabl sensor provid patient conveni improv patient complianc vs tradit devic holter monitor use extern
compliance/eas use highlight patient prefer zio tradit monitor consid zio comfort vs tradit holter
patient mark symptom occur wear devic separ record contextu data diari activ circumst
better allow physician match symptom ecg activ
follow wear period zio patch return data upload irtc cloud time electron report provid physician
larg replac epatch point
lightweight lead wire configur micro patch attach bodi product waterproof
stick connect chest
patient mark symptom occur wear devic separ record contextu data activ circumst symptom
diari allow physician match symptom activ ecg data
launch
acquir epatch delta danish electron compani launch product us march
compliance/eas use highlight nurs said epatch simpler tradit ecg equip could appli
patient indic devic interf daili life accord survey epatch applic
data download comput physician offic potenti could improv turnaround time compar devic like zio
requir data upload cloud process provid physician
monitor extend recharg
allow use one patch per monitor session reusabl sensor patch format
major extend holter sale phase cardiokey
page
deep dive cardiac monitor market background
ambulatori ecg devic market product growth categori
sternum base technolog sold either hour day patch
sold product offer vs servic patient bring devic directli doctor interpret
elimin need certifi third-parti cardiac team analyz data typic expens time consum aspect
process physician drawn report gener process success competitor space irhythm champion
valu driver physician
fda approv full commerci launch began octob
provid real-tim commun devic monitor center physician notif
devic oper holter monitor switch mode tradit mcot
indic wear compar zioat wear
patch continu monitor handheld transmitt
dedic center certifi cardiograph technician monitor real-tim patient inform allow user respond sever arrhythm
clinic seeq perform studi devic detect arrhythmia patient rct studi
page
compani mention note
johnson johnson rate
heart-car corpor america privat
kaila krum herebi certifi view express research report accur reflect person view subject compani
secur also certifi receiv direct indirect compens exchang
express specif recommend report
page
